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ABSTRACT 
Mammographic density is one of the strongest risk factors for breast cancer and has 
been thoroughly studied as such. Extensive mammographic density also decreases 
screening sensitivity, thereby increasing the risk of interval cancers. Whether density 
acts as fertile ground for all types of breast cancer, or whether it influences tumor 
growth in a specific direction, was not known when we embarked upon the studies of 
this thesis. We therefore aimed to investigate the association between density, tumor 
characteristics, molecular subtypes, recurrence, and survival, focusing on interval 
cancers in the last study.  
For studies I, III, and IV, we used the cases included in a population-based case-
control study, in which cases were all Swedish women, aged 50-74, with incident 
breast cancer, diagnosed 1993-1995 (n=3345). We only included postmenopausal 
women with no prior history of cancer other than non-melanoma skin cancer and 
cervical cancer in situ (n=2720). Of these women, 1774 women had eligible 
mammograms.  
For study II, in which we investigated the relationship between density and 
molecular subtypes, the study population was based on all women with breast cancer 
operated at a large university hospital in Stockholm 1994-1996 (n=524). Women with 
available gene expression profiling and mammograms were included in the study 
(n=110).  
Pre-diagnostic/diagnostic density of the unaffected breast was assessed using a 
semi-automated, computer-assisted thresholding technique, Cumulus. Density was 
either measured as the dense area in cm
2 
(absolute density=AD) or percentage density 
(PD) (the absolute dense area/the total breast area). 
We did not find an association between density and tumor characteristics (lymph 
node metastasis, hormone-receptor status, grade, and histopathological classification) 
except for tumor size. However, this association seemed at least in part to be due to 
masking delaying diagnosis. In accordance with the lack of association between PD and 
most tumor characteristics, we did not find an association between density and 
molecular subtypes, nor between density, distant recurrence, and survival. We did, 
however, see a relatively strong association between PD and both local and 
locoregional recurrence, independent of established risk factors.  
In the last study, we investigated the differences in survival between interval 
cancers and screening-detected cancers, taking mammographic density into account. 
We could show that interval cancers in both dense and non-dense breasts were 
associated with poorer prognosis compared to screening-detected cancers. However, 
the poorer prognosis seen in interval cancers in dense breasts seemed mainly 
attributable to delayed detection, whereas the group of interval cancers in non-dense 
breasts primarily seemed composed of truly aggressive tumors which we believe need 
further study. 
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1 INTRODUCTION 
 
Breast cancer is the most common cancer in women in Sweden and worldwide. 
Survival has improved greatly over the past decades, due to, among other things, 
mammography screening and adjuvant therapy. However, ~1500 women still die of 
breast cancer each year in Sweden. Although 5-year breast cancer survival is high, 
which for most diseases reflects the curability of disease, a woman is unfortunately 
never cured of breast cancer. She may therefore die from the disease even 20-30 years 
after diagnosis. 
 
Over the past decade, there has been growing evidence that breast cancer is not one 
disease, rather it is composed of several different subtypes. These are heterogeneous 
with respect to etiology, tumor characteristics, response to treatment, and prognosis. 
Certain tumors could be described as indolent whereas others are highly aggressive. 
Unfortunately, the currently clinically available prognostic factors are unable to 
correctly stratify tumor subtypes; some women will therefore die despite adjuvant 
therapy, and some women will receive adjuvant therapy who do not need it. 
 
Mammographic density is one of the strongest risk factors of breast cancer but its role 
in breast cancer development is poorly understood. The studies that form the basis of 
this thesis aimed to investigate the role of mammographic density in carcinogenesis and 
tumor progression. Is mammographic density a seedbed for all types of breast cancer, 
or is it associated with a certain subtype or behavior? We hereby hoped to shed light on 
breast cancer biology and to add valuable information to established prognosticators in 
order to improve breast cancer care. 
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2 BACKGROUND 
 
2.1 THE NORMAL BREAST 
 
2.1.1 Breast anatomy and physiology 
 
The breast lies on top of the pectoralis major muscle. It is composed of parenchyma, 
stroma, and fatty tissue as well as skin and subcutaneous tissue. Bands of connective 
tissue called Cooper’s ligaments are attached to the fascia of the skin and the pectoralis 
major muscle, holding the breast in place. As women age, these ligaments relax, 
leading to ptosis of the breast. Dimpling of the skin, a sign of breast cancer, is caused 
by tumor invasion of the ligaments of Cooper. 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The anatomy of the breast (1) 
 
The breast parenchyma consists of 15-20 lobes each drained by one major lactiferous 
duct. Every lobe of the breast contains a system of ever-branching ducts ending blindly 
in a network of terminal ductules. A cluster of terminal ductules and their duct of origin 
compose a lobule which is surrounded by a specialized stroma. The terminal ductal 
lobular units (TDLU:s) include the terminal ductules, and their specific extra- and 
intralobular terminal duct (Figure 2). The TDLU:s are the functional units of the breast, 
producing and secreting milk. It is within these that most breast cancers occur; lobular 
cancers originating from the terminal ductules and ductal cancers from the ducts. The 
ducts are lined by an inner layer of luminal epithelial cells consisting of secretory cells, 
hormone receptor-expressing cells (2), and progenitor cells (3, 4), and an outer layer of 
basal cells consisting of myoepithelial cells (2), which have the ability to contract when 
stimulated by oxytocin, and mammary stem cells (5, 6). Milk is transported from the 
TDLU:s through interlobular ducts which merge and drain into the major lactiferous 
ducts. The major lactiferous ducts dilate into sinuses beneath the areola in which milk 
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can accumulate and these are in turn connected to 6-10 openings in the nipple through 
which the milk exits.  
 
 
 
Although the breast epithelium is the functional part of the breast, it is only a minor 
component of the breast; the majority of the breast is composed of stroma and fatty 
tissue. During menopause the amount of epithelium diminishes as it involutes and is 
replaced by fatty tissue (see 2.1.2 Breast development).   
 
For clinical purposes, the breast is further divided into the area behind the areola and 
the quadrants which compose the rest of the breast. The upper, outer quadrant contains 
the most breast tissue, and it is also here most breast cancers occur. 
 
The breast parenchyma and nipple-areola complex are supplied with blood through 
several arteries, of which the internal mammary artery accounts for more than half of 
the blood supply to the entire breast parenchyma. The circulus venosus which is 
situated around the nipple, carries blood from the breast towards the axilla into the 
internal thoracic and axillary vein. The breast is thus richly vascularized and 
hematogenic, metastatic spread is not uncommon as the disease progresses. The most 
common sites of metastasis are bones, liver, and lungs (7). 
 
Most of the lymphatic drainage of the breast goes to the axillary lymph nodes (75%), 
which is why it is the most common initial location of metastasis. The number of 
lymph nodes varies between individuals and also depends on what is defined as the 
axillary lymph nodes since this depends on method of dissection, but the span of 12-40 
axillary lymph nodes is commonly reported (7). Other regional lymph nodes are 
situated within the breast (the internal mammary chain), parasternally, and above and 
below the clavicula. 
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2.1.2 Breast development 
Breast development starts during embryonic life but is only fully developed and 
differentiated by the end of the first full-term pregnancy. During the fifth week of 
embryonic life, the ‘milk streak’ forms, which is a thickening of the ectoderm from 
the axilla to the groin (8). During weeks 6-7 the mammary crest forms which is a 
thickening in the thoracic region, and the rest of the milk streak involutes (8). This is 
also when the nipple primary bud takes form. The primary bud penetrates the 
mesenchyme and eventually leads to the development of 15-20 secondary buds which 
become the lactiferous ducts and their branches (9). 
During puberty, lobule formation occurs (9) and the deposition of fatty tissue 
increases breast size (10). Still 80% of the breast consists of stromal tissue (8) which 
includes fibroblasts, endothelial cells, immune cells, and extracellular matrix. During 
pregnancy, the distal parts of the ducts proliferate. The epithelial cells in the acini 
both increase in number and size, and differentiate into secretory cells that can 
synthesize and secrete milk (9). The breast has only now become fully differentiated. 
The mammary gland changes little morphologically during lactation. However, 
cessation of lactation causes post-lactational involution to occur. During this process, 
epithelial and stromal tissues go into apoptosis and regress, and stromal remodeling 
ensues (11). The lobules go into a resting non-secretory state, but still appear more 
complex/developed than the lobules of nulliparous women (11).     
Involution also occurs as an aging-process (12) and is especially marked during 
menopause (10) in response to the ceasing ovarian hormonal secretion (11). 
Involution results in a decrease of both number of acini per lobule and size of acini. 
Furthermore, the intralobular stroma is replaced by denser collagen to finally be 
replaced by fatty tissue (12).  
 
2.2 BREAST CANCER 
2.2.1 Descriptive epidemiology 
2.2.1.1 Incidence 
Breast cancer is the most common cancer in women worldwide. 1.38 million new 
breast cancer cases were diagnosed 2008 (23% of all cancers in women) (13). 
However, incidence rates vary from 19.3 per 100,000 women in Eastern Africa to 89.9 
per 100,000 women in Western Europe (13). The differences in incidence are due to 
variations in environmental factors rather than genetic factors (14, 15), which is well 
illustrated by migrant studies which show an increase in risk for migrants moving from 
a low-risk to a high-risk country (16) and that the risk increases from generation to 
generation (17). Thus, parallel with the progress of the developing countries and the 
adoption of a more westernized lifestyle, incidence of breast cancer is also increasing in 
these countries (18).  
 
Breast cancer is also the most common cancer in women in Sweden; approximately 
8000 women developing breast cancer every year (19). The number of effected women 
has been steadily increasing by 1.3% since 20 years, but the last 10 years, the increase 
has been weaker (0.9%) (20). This may partially be due to the drastic drop in hormone-
replacement therapy prescription which decreased after the Women’s Health Initiative 
(WHI) hormone trial showed adverse effects of hormone-replacement therapy (21). 
Lambe et al. (22) studied the incidence of breast cancer in postmenopausal women in 
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Sweden between 1997 and 2007 and the possible correlation with hormone-
replacement therapy prescription. They found that breast cancer incidence had 
significantly decreased from 2003 in the age group 50-59 and concluded that this 
decrease was likely due to a decline in hormone-replacement therapy use(22). A 
decline in breast cancer incidence has been noted in several Western countries (23-31) 
and saturation in mammography screening has been proposed as another possible 
explanation to the decline in breast cancer incidence (32).  
 
2.2.1.2 Mortality and survival 
Mortality is usually measured as a rate and refers to the rate of individuals dying from a 
particular disease compared to the general population. Mortality is influenced by the 
incidence and survival of disease and is a particularly important measure of the burden 
of disease (33). Conversely, survival rates measure the rate of dying within a cohort of 
individuals with the disease. Survival is not an adequate measure for e.g. evaluating 
screening programs since these programs aim to diagnose disease earlier, which will 
increase survival “artificially” (see 2.2.5.2 Mammography screening). Thus, mortality 
is the preferred estimate for evaluating secondary preventive measures. However, to the 
individual patient, survival is of utmost importance since it estimates the risk of that 
individual dying compared to other individuals with the disease.  
 
Since breast cancer survival is much higher in developed regions where the incidence is 
highest, the range of mortality rates is smaller (~6-19 per 100,000) than the range of 
incidence rates (13). It is the most common cause of death among women worldwide 
(269,000 deaths in developing regions and 189,000 deaths in developed regions) (13).  
In Sweden, breast cancer was also the most common cause of death from cancer in 
women until 2005, but is now the second most common cause of death from cancer 
after lung cancer (34). In 2011, 1401 Swedish women died from breast cancer (35).  
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Figure 3. Trends in female breast cancer incidence and mortality in Sweden. Data from 
Nordcan (Association of the Nordic Cancer Registries). 
 
 
2.2.1.3 Prevalence 
Since breast cancer is relatively common and survival is high (the 5-year breast cancer 
specific survival is 86%), the prevalence of disease is high. In 2009, approximately 
89000 Swedish women were living with breast cancer (36). 
 
 
2.2.2 Breast cancer biology  
2.2.2.1 Carcinogenesis 
2.2.2.1.1 The somatic mutation theory 
Cancer evolves through a multi-step process which is initialized by the genetic 
mutation of a single cell, either caused by environmental factors, germ-line mutations, 
or spontaneously. The mutated cell gives rise to a clonal expansion of genetically 
damaged cells, in which further mutations in oncogenes and tumor suppressor genes 
lead to uncontrollable growth and deranged cellular architecture and orientation, 
resulting in a cancer cell. During this clonal evolution, the ensuing cancer cells also 
acquire invasive and metastatic capability. Genetic alterations may continue to occur 
and accumulate in the cancerous cells, which may affect proliferation rate, the degree of 
invasiveness, and metastatic potential. 
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In 2000, Hanahan and Weinberg proposed that there were six essential changes in cell 
function that lead to cancer development: self-sufficiency in growth signals, 
insensitivity to growth-inhibitory signals, escape from programmed cell-death 
(apoptosis), unrestricted replicative potential, sustained angiogenesis, and tissue 
invasion and metastasis (37). However, as pointed out by Yuri Lazebnik, only the last 
criterion of tissue invasion and metastasis differentiates malignant tumors from benign 
tumors (38). This is also an important distinction between in situ cancers (which do not 
penetrate the myoepithelial basement membrane) and invasive cancers.  
 
Based on the advances in cancer research the past decade, Hanahan and Weinberg 
updated their proposed hallmarks of cancer in 2011 to include two emerging hallmarks: 
Evasion of immune destruction and reprogramming of energy metabolism to support 
unceasing cell growth and proliferation (39). Furthermore, they highlighted the role of 
genomic instability and tumor-promoting inflammation in cancer progression. Genomic 
instability increases the amount of mutated cells, leading to a high degree of diversity 
between cancer clones, which is beneficial for tumor survival. This may, however, also 
occur through epigenetic alterations such as DNA methylation and histone 
modifications (39).  
 
2.2.2.1.2 The tissue organization field theory 
A paradigm shifting hypothesis pertaining to the development of somatic cancer is the 
‘tissue organization field theory’ proposed by Ana Soto and Carlos Sonnenschein in 
1999 (40). It suggests two fundamental principles. First, in contrast to the prevailing 
paradigm of the default state of cells being quiescence, it proposes that the normal state 
of cells is proliferation. The second premise is that carcinogenesis is a collapse of tissue 
organization rather than an acquisition of crucial genetic mutations. Although 
proliferation is presented as the default state of cells, cell-adhesion-dependent tissue 
architecture is believed to restrict proliferation (41). A disturbance of stromal-epithelial 
interactions may cause a dysfunction of cell adhesion and/or a loss of tissue 
organization, which would be able to stimulate normal cells into transforming into 
malignant counterparts even in the absence of genetic mutations (41). Moinfar et al. 
(42) observed that genetic alterations and loss of heterozygosity was common in the 
stromal DNA adjacent to the primary breast tumor. Even more intriguing, they found 
that genetic alterations in the stroma seemed to precede genetic changes in the 
epithelium in some cases.  
 
In line with the above, tissue reorganization affects tissue stiffness, which is now 
known to be an important modulator of cell proliferation, survival, migration, and 
differentiation (43). In recent years, tissue stiffness has also been shown to be 
associated with both breast tumorigenesis and progression (44). In the same study, it 
was shown that tissue stiffness was associated with collagen cross-linking, and the 
authors remarked that this may explain why mammographic density increases breast 
cancer risk (44).    
 
2.2.2.1.3 Cancer is a tissue disease 
Until recently, tumors were viewed as a homogeneous group of cancer cells. However, 
it is now known that tumors are heterogeneous, including cancer stem cells, cancer-
associated fibroblasts (CAFs), immune inflammatory cells, pericytes, and endothelial 
cells apart from the cancer cells themselves (39). These cells, including the surrounding 
extracellular matrix, are referred to as the tumor microenvironment. Interaction 
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between the tumor microenvironment and the tumor cells has been shown to be 
essential to tumor progression (39). CAFs, for example, effect cell proliferation, 
angiogenesis, invasion, and metastasis (39).  
 
The stromal cells of the microenvironment are recruited from adjacent normal tissue 
(either as preexisting stromal cells or as stem/progenitor cells,) as well as from the bone 
marrow (39). When the mesenchymal stem and progenitor cells reach the tumor, they 
may either remain undifferentiated, become partially differentiated or fully differentiate 
into the different stromal cell types (39). 
  
2.2.2.2 Metastasis 
Metastasis occurs when tumor cells from the primary tumor migrate to distant sites in 
the body and form a secondary mass at that place. For this to happen, a tumor cell must 
detach from adjacent cells and invade the surrounding stroma. It then has to be able to 
enter lymphatic channels or blood vessels (intravasation), survive the mechanical forces 
of circulation, avoid circulating immune cells, and exit the vessels through a process 
called extravasation (45). Once at the new site, the tumor cell must adapt to the new 
environment. It also needs to acquire the ability to proliferate without the stimulation it 
formerly received from the microenvironment of the primary tumor, and in spite of 
inhibitory signals from the new microenvironment (46). Finally, it needs to be able to 
develop a vascular system that can support proliferation (47).  
 
As previously stated, metastasis can either spread via the lymphatic channels or blood 
vessels. In breast cancer, the former gives rise to lymph node metastasis most often 
occurring in the ipsilateral axilla, whereas hematogenic/systemic spread usually gives 
rise to metastasis in the bones, lungs, liver, or brain. Breast cancer that is spread to any 
of the latter sites is referred to as distant metastasis. It is not uncommon to present with 
axillary lymph node metastasis at diagnosis, and this is still a curable disease since the 
spread is well-confined. The opposite is true for distant metastasis, which is uncommon 
at first presentation, can affect several organs at once and several parts of the same 
organ, and for which only palliative therapy exists (7).  
 
2.2.2.3 Recurrence 
Recurrence of disease refers to relapse at any site, i.e. locally (in the residual breast, 
chest wall, or scar tissue), regionally (in the regional lymph nodes), or in distant organs 
(distant metastasis). Local and regional recurrence can also be combined and is then 
referred to as locoregional recurrence. Unlike distant metastasis, which is closely 
related to breast cancer death, locoregional recurrence is only moderately associated 
with breast cancer survival; for every four locoregional reccurences that are avoided, 
one breast cancer-specific death over the next 15 years is evaded (48).  
 
2.2.3 Risk factors 
2.2.3.1 Sex 
Breast cancer is the most common cancer in women, while it is a very rare disease in 
men. In 2010, almost 8000 women were diagnosed with breast cancer in Sweden and 
only 33 men (49). Sex is therefore a very strong risk factor of breast cancer. 
 
 9 
 
2.2.3.2 Age 
Breast cancer incidence increases with age and is relatively rare in women less than 40 
years of age, after which the incidence increases greatly (7, 33) (Figure 4). Conversely, 
the rate of the age-specific incidence rises steeply until around 50 years of age (i.e. 
around menopause), after which the increase is less pronounced (33, 50), suggesting 
that hormones are important to breast cancer development (33).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Breast cancer incidence in women per 100,000 individuals. Sweden, 2010. 
Data from the Swedish Cancer Registry. 
 
 
2.2.3.3 Mammographic density 
Mammographic density is one of the strongest risk factors of breast cancer. When 
measured quantitatively, a percentage density (PD) ≥75% has a 5-fold increased risk of 
breast cancer compared to women with PD<5% (51) (see 2.3 “Mammographic 
Density” below).  
 
2.2.3.4 Heritability 
A family history of breast cancer in a first-degree relative increases risk of breast 
cancer by approximately 2-fold (52), and a family history of more than one first-degree 
relative confers an even greater risk. Approximately 16% of breast cancers in women 
with a positive family history are thought to arise due to mutations in the high 
penetrance susceptibility genes BRCA1 and BRCA2 (53). High-penetrance 
susceptibility genes are characterized by the fact that carriers have a high likelihood of 
developing disease. The lifetime risk of developing breast cancer is 45-65% for carriers 
of BRCA1 and BRCA2 mutations (54), and is even higher for early-onset breast cancers 
(55). Furthermore, BRCA1 and BRCA2 both increase risk of ovarian cancer. There are 
four other known high penetrance genes associated with breast cancer,TP53, PTEN, 
STK11, and CDH1, but mutations in these genes are very rare and together all six genes 
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are only believed to account for 20% of the familial risk of breast cancer (55). Four, 
intermediate penetrance genes have also been identified: CHEK2, ATM, BRIP1 and 
PALB2. These increase breast cancer risk by 2-4 fold but are also believed to be 
uncommon (55). Thus, the majority of breast cancers, even cases with family history, 
are thought to be polygenic, i.e. attributable to a combination of genetic variants each 
conferring a low risk. In order to find these low penetrance alleles, genome-wide 
association studies (GWAS) are carried out to compare single nucleotide 
polymorphisms (SNPs) (common inter-individual or inter-allelic base pair differences) 
in breast cancer cases and controls. However, since effects of the individual SNPs on 
breast cancer risk are small, large study populations are needed. GWAS are conducted 
without à priori knowledge and are thus hypothesis-generating. Indeed, GWAS has 
managed to shed new light on breast cancer biology; new susceptibility genes have 
been identified that are not, as the previously identified susceptibility genes (e.g. 
BRCA1/2, BRIP1, CHEK2), associated with DNA repair and sex hormone synthesis, 
but with cell proliferation and cell signaling, e.g. FGFR2 and MAP3K (56). 
 
 
2.2.3.5 Endogenous hormones 
Breast cancer is influenced by many hormonally related factors (see below) and it has 
therefore long been assumed that high levels of endogenous sex hormones are partially 
at fault. This was also corroborated when the Endogenous Hormones and Breast 
Cancer Collaborative Group showed that postmenopausal women who had increased 
levels of endogenous sex hormones, also were at higher risk of breast cancer and there 
was a dose-response relationship (57). Eliassen et al. observed a relationship between 
higher levels of free estradiol during the follicular phase and breast cancer risk in 
premenopausal women (58). Two studies that directly assessed endogenous 
progesterone and its relationship to breast cancer risk showed no associations (58, 59). 
Missmer et al. also tested for an interaction between estrogen and progesterone but did 
not find any evidence of this (59), which is surprising since especially combinations of 
HRT (estrogens in combination with progestagens) increase breast cancer risk (see 
below). The authors speculated that this could be due to differences between 
endogenous progesterone’s and synthetic progestin’s metabolic effects on breast tissue.  
 
2.2.3.6 Reproductive factors 
Age at menarche influences breast cancer risk, where older age decreases risk (60). The 
opposite is true for age at menopause, where older age at menopause increases risk of 
breast cancer (61). Hence, the longer a woman has menstrual cycles, the higher her risk 
of breast cancer. 
 
An early age at first full-term pregnancy and number of full-term pregnancies both 
have protective effects on breast cancer risk, independent of each other (62). The reason 
for this is thought to be that mammary gland cells are undifferentiated until first 
pregnancy, and that each pregnancy decreases the number of undifferentiated cells. 
However, the effect of pregnancy is dual; a full-term pregnancy increases breast cancer 
risk immediately after birth, but the risk then gradually diminishes and, in the long-
term, imparts a protective effect (63). Breast-feeding also has a protective effect on 
breast cancer risk independent of age at first birth and parity (63, 64). The 
Collaborative Group on Hormonal Factors in Breast Cancer estimated that each birth 
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conferred a decrease in relative risk (RR) of breast cancer of 7.0% and every 12 months 
of breast feeding conferred a decrease in RR of 4.3% (64). 
 
2.2.3.7 Anthropometric factors 
 
As with pregnancy, BMI also has a dual effect on breast cancer. Childhood and 
adolescent obesity is protective of breast cancer, possibly due to obesity being 
associated with fewer menstrual cycles (65). Conversely, in postmenopausal women, 
obesity increases risk of breast cancer. This may be due to obese postmenopausal 
women having higher levels of bioavailable estradiol (65), since the main source of 
estrogens in postmenopausal women is the conversion of androgens to estrogens in the 
adipose tissue (66). Another anthropometric measure associated with breast cancer risk 
is height, which is weakly and positively correlated with risk (67); a 10-cm increment 
in height increasing RR by 17%. The cause of this relationship is, however, unclear.  
 
2.2.3.8 Exogenous hormones 
The use of combined oral contraceptives is related to an increase in breast cancer risk of 
about 25% but is only associated with current or recent use (63). 10 years after 
cessation there seems to be no increased risk (63).   
 
Hormone-replacement therapy (HRT), given as a combination of estrogen and 
progesterone or estrogen alone, increases breast cancer risk, where combination 
treatment increases risk the most (68). Risk also increases with duration, e.g. in women 
on combination therapy, breast cancer risk increases by 7.6%/year (69). However, the 
increased risk gradually disappears within 2 years of cessation (70). The effect of HRT 
on breast cancer risk is larger in lean women (68) and women with high 
mammographic density (71).  
 
2.2.3.9 The intrauterine environment 
In 1990, Dimitrios Trichopoulos hypothesized that breast cancer may originate in 
utero (72). He suggested that the high estrogen levels created a “fertile soil” that was 
more susceptible to cancer initiation. Many studies have evaluated this hypothesis, 
mainly using birth weight as a proxy of intra-uterine exposure to estrogens and other 
growth factors such as insulin and the insulin-like growth factors (IGF) I and II which 
also may influence breast cancer risk (73). Three meta-analyses have confirmed that 
there is a positive correlation between birth weight and breast cancer risk (73-75), 
especially in pre-menopausal breast cancer (73, 74). The intrauterine environment 
thus seems to influence mammary carcinogenesis. However, whether this is due to 
increased growth factors and the mechanism by which they would act, remains to be 
revealed.  
 
2.2.3.10 Previous benign breast disease 
An important distinction of benign breast disease when discussing its relation to breast 
cancer, is whether it is a non-proliferative or proliferative lesion, and whether the latter 
has presented with or without atypia. Non-proliferative lesions do not or only slightly 
increase breast cancer risk (76), whereas proliferative lesions are strong risk factors for 
breast cancer. Proliferative lesions without atypia are associated with a doubling of 
breast cancer risk, and proliferative lesions with atypia increase risk by at least 4-fold 
(63). 
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2.2.3.11 Lifestyle factors 
Alcohol intake is associated with a moderate increase in breast cancer risk (77), while 
most studies have not found an association between smoking and breast cancer (78). 
Moderate physical activity seems to have a protective effect on breast cancer risk; a few 
hours of vigorous exercise per week may decrease risk by about 30% (63). However, 
studies on the relationship have been somewhat inconsistent and the effect of physical 
activity on breast cancer risk has varied between studies (63). 
 
Although several factors associated with different aspects of our diets have been 
hypothesized to be associated with breast cancer risk, associations are modest at best 
and results inconsistent (33). However, for vitamin A, carotenoids, and folate a modest 
protective effect on breast cancer risk has consistently been shown (33).    
 
2.2.3.12 Ionizing radiation 
Studies of the effects of ionizing radiation on breast cancer risk have primarily been 
carried out on Japanese atomic bomb survivors and patients exposed to ionizing 
radiation in the diagnostic or therapeutic, clinical setting. There was a large variation in 
the doses the different populations received to the breast; from 0.02 Sievert (Sv) to >20 
Sv (79). According to these studies there seems to be a dose-response relationship 
between ionizing radiation and breast cancer risk (79). Furthermore, risk seems to 
attenuate with age (and breast maturation) so that girls who are exposed before 20 years 
of age have the highest risk of breast cancer, whereas the risk in postmenopausal 
women is negligible (79). There may also be an increased breast cancer risk associated 
with ionizing radiation in pregnant women (79). 
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Table 1. Risk factors of breast cancer 
 
Risk factors Strength of 
association* 
Clarifications 
Sex ↑↑↑ Females 
Age ↑↑↑ Risk increases with age 
Mammographic density ↑↑↑ PD≥75% compared to PD<5% 
Geographical region ↑↑↑ Developed countries vs. 
developing countries 
Previous benign breast 
disease 
↑↑↑ Atypical hyperplasia 
Family history ↑↑ First-degree relative, also increases 
with number of effected relatives 
BMI postmenopausal ↑↑ High BMI increases risk 
HRT ↑↑ Especially combined HRT 
Age at menopause ↑↑ Older age 
Age at menarche ↑↑ Younger age 
Age at first birth ↑↑ >30 compared to <20 
Ionizing radiation ↑↑ Before age 20 
Alcohol intake ↑ Risk increases with increased 
intake 
Oral contraceptives ↑ Current use 
Height ↑ Risk increases with increased 
length 
Birth weight ↑ Risk increases with increased birth 
weight 
Previous benign breast 
disease 
↔ Fibroadenomas  
Breast feeding ↓ Longer periods of breast feeding 
decreases risk 
Parity ↓ Long-term protective effect of 
parity 
BMI premenopausal ↓ High BMI is protective 
Physical activity ↓ Physical activity is protective 
 
*↑↑↑ Strong risk factor; ↑↑ Moderate risk factor; ↑ Weak risk factor; ↔ no association;  
↓ protective factor. 
 
 
2.2.4 Risk prediction models 
The Gail model was originally developed by Gail et al. in 1989 (80) and is now a 
publicly available tool for prediction of breast cancer risk 
(http://www.cancer.gov/bcrisktool) . The model uses the variables age, age at 
menarche, age at first birth, family history of breast cancer in a first-degree relative, 
number of previous breast biopsies, atypical hyperplasia, previous breast cancer 
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(invasive and in situ), and ethnicity to calculate risk (atypical hyperplasia and ethnicity 
have been added later on (81)). One caution with the Gail model is that it has not 
updated the age-specific incidence rates on which it is based, and this may be one of the 
reasons that it underestimates breast cancer risk on the individual level (82).  
 
Since the Gail model mainly includes non-genetic risk factors, the Claus (83) and Ford 
(84) models were developed which both focus on family history of breast cancer. The 
latter also includes family history of ovarian cancer to identify individuals with BRCA 
mutations. The Tyrer-Cuzick model tries to incorporate both information on 
endogenous estrogen exposure, history of benign breast disease, and a comprehensive 
family history assessment (85). According to an evaluation of the four different models 
(86), they all performed similarly pertaining to individual risk assessment, but the 
Tyrer-Cuzick model was somewhat better at predicting overall number of cases.  
 
A limitation of all models is that none of them have been validated in the general 
population (87). Furthermore, none of the models include mammographic density or 
genetic alterations. There have been attempts to incorporate mammographic density 
into risk prediction models, but this has only lead to moderate improvements in 
prediction (87). However, this may be explained by the correlation between 
mammographic density and the other breast cancer risk factors such as parity, age at 
first birth, and benign breast disease. Tice et al. (88) namely showed that a model 
including only age, ethnicity, and mammographic density performed as well as the Gail 
model. Further, Barlow et al. (89) showed that both age and mammographic density 
were highly predictive when studied independently, but that adding mammographic 
density to a model including traditional risk factors did not increase predictive power.  
 
 
2.2.5 Diagnostics 
2.2.5.1 Triple diagnostics 
Breast cancer is diagnosed through triple-diagnostics, referring to the triad 
mammography, clinical assessment, and cytology. Nowadays, ultrasound is also often 
added as a complement to mammography, and courser needle biopsies may be taken in 
addition to cytology (7). About half of all breast cancers diagnosed in Sweden today are 
diagnosed within the screening program (7). These are usually asymptomatic cancers 
(7). The rest of the cancers are clinically detected as symptomatic cancers and most 
often present as a lump in the breast, but other symptoms such as a lump in the axilla, 
breast discomfort, redness of the skin, or nipple secretion can also occur. The majority 
of women diagnosed with symptomatic cancers are women who are not invited to 
screening, but also consist of women who were invited but chose not to attend 
screening (7). Furthermore, breast cancer may be detected in the interval between two 
screening examinations as a symptomatic cancer, either because a cancer was missed at 
the previous screening or because it is highly proliferative (see 2.2.5.2.2. Interval 
cancers).  
 
High mammographic density lowers mammographic sensitivity (90). Consequently, 
other breast imaging modalities are used in populations where high mammographic 
density is prevalent. Ultrasound is for instance preferred in young (<30 years of age), 
pregnant, and lactating women (7), all of whom have high mammographic density. In 
women with a strong family history or carriers of e.g. BRCA1 or BRCA2 mutations, 
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who are recommended yearly follow-up from age 25-35 years of age (91-93), MRI is 
preferred also due to the younger age group and higher mammographic density. 
However, MRI is also favored in these women since BRCA2 carriers have an increased 
risk of lobular cancer (94) which are difficult to detect on a mammography (95), and 
BRCA-associated tumors may be more likely to have a benign appearance on 
mammography (96, 97). MRI is not only used in individuals with family history, but 
may also be used to further investigate unclear radiologic findings. The drawback of 
MRI is that, although sensitivity is high, specificity is lower than that of mammography 
(98), increasing the risk of false positive findings. 
 
Galactography/ductography is also an alternative radiologic examination of the breast if 
a woman suffers from serous or bloody discharge from the nipple.  It is carried out by 
injecting contrast material into the secreting duct in order to visualize intraductal 
proliferative disease, e.g. papillomas, and also allows for cytological examination of the 
discharge. Sensitivity is, however, low (7). 
 
2.2.5.2 Mammography screening 
2.2.5.2.1 History and guidelines 
Mammography screening was implemented in Sweden in order to decrease breast 
cancer mortality. Screening programs were introduced in 1986 and were implemented 
in all of Sweden by 1997. The initial recommendations that came in 1986 included 
women from 40-74 years of age. However, two amendments were made in 1987 and 
1988, respectively, allowing county councils that were short of staff to only include 
women between 50-69 years of age (99). Different county councils therefore included 
different age groups. In 1995-1996, for example, 11 out of the 25 participating county 
councils invited women 40-74 years old, six invited women 50-69 years old, and the 
eight remaining invited women between these two age spans (99).  
 
The interval between screening examinations is between 1,5-2 years in Sweden. It is 
based on the time difference between the point at which a tumor first becomes 
detectable on a mammography (at 3-4 mm) and the point at which it becomes 
symptomatic. The length of this pre-symptomatic phase at which the tumor is 
detectable at screening has been estimated to be approximately 1,5-3 years in most 
cases (100).  
 
2.2.5.2.2 Interval cancers 
Interval cancers are symptomatic cancers diagnosed in the interval between two 
screening examinations, where the prior screening mammography was negative (or 
inconclusive with a negative follow-up). Since mammography does not have 100% 
sensitivity, some cancers will not be detected at mammography screening either due to 
observer error, unspecific findings, or masking, and therefore diagnosed as interval 
cancers. These are viewed as “false” interval cancers. Highly proliferative tumors may, 
however, also arise in the interval between two screening examinations, and these are 
referred to as “true” interval cancers. The latter are thought to be more aggressive and 
have a poorer prognosis than screening-detected cancers (101).  
 
The number of interval cancers is used as a measure of the quality of the screening 
program. For the quality of the screening program to be acceptable, the percentage of 
interval cancers should not exceed 30% of the estimated breast cancer incidence 
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without screening the first year after a negative screen, and not exceed 40% the second 
year (100).  
 
2.2.5.2.3 Views 
The mammogram views routinely used in screening programs are the medio-lateral 
oblique (MLO) and the cranio-caudal (CC) views. The CC view is taken straight from 
above and the MLO view is taken at an angle of 30-60 degrees medially of the CC 
view. The MLO view constitutes the basis of the Swedish mammography screening 
program, but CC views are often added to increase detection rate. At the first 
mammography a woman ever does (the baseline mammography), both the CC and the 
MLO views are taken. When performing a diagnostic mammogram, both the MLO and 
CC views are used and a lateral view (90 degrees lateral of the CC view) is usually also 
added to further increase the detection rate.  
 
2.2.5.2.4 Biases in estimating the effect of screening on mortality   
The aim of mammography screening is to reduce breast cancer mortality. However, 
comparisons between screening- and non-screening-detected cancers to evaluate the 
efficiency of mammography screening suffer from several biases e.g. selection bias, 
lead-time bias (see figure 5), and length bias (see figure 6). Selection bias refers to 
women attending screening being different from non-attenders; they are more often of 
higher socio-economic status and health-conscious which increases their life-
expectancy. Lead-time bias refers to tumors diagnosed at screening being detected 
earlier during their natural history than tumors detected otherwise; screening will then 
advance detection of disease and result in a survival advantage independent of whether 
it actually prolongs survival or not. Tumors detected by mammography screening are 
generally therefore of lower stage than symptomatic cancers, a phenomenon called 
stage shift (102). The length bias refers to differences in tumors’ proliferation rates; 
indolent tumors spend a longer time in an asymptomatic phase and are thus more likely 
to be detected at screening, whereas fast-growing tumors have a shorter asymptomatic 
phase and are thus more likely to be detected between screening rounds. 
 
 
 
Figure 5. Lead-time bias refers to the artificial survival advantage a pre-symptomatic 
tumor has compared to a clinically detected tumor, due to the former being diagnosed 
earlier during its natural history. 
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Figure 6. Length bias. Tumor 1 is a more highly proliferative and aggressive tumor 
with a much shorter pre-symptomatic phase than tumor 2 which is a more indolent 
tumor. Tumor 2 will thus more likely be diagnosed at screening than tumor 1 which 
will more likely be diagnosed between screening rounds. This will affect survival 
comparisons and is referred to as the length bias.  
 
 
2.2.5.2.5 The screening debate 
Several Swedish randomized controlled trials have been carried out to assess the effect 
of mammography screening on mortality. They have shown reductions in mortality of 
approximately 25% for the general population and even more for the women who 
participated in screening (103-105). However, a Cochrane review by Gotzsche and 
Nielsen of all eligible and completed randomized trials comparing breast cancer 
mortality in screened vs. non-screened women, has questioned the results of the trials 
(106). Among other things, the trials were accused of having had a suboptimal 
randomization process and biased assessment of breast cancer mortality (this critique 
was later refuted by Nyström et al. (104)). Yet, in spite of these objections, it was still 
calculated that mammography screening reduces breast cancer mortality by 15-20% 
(106). However, it was also estimated that screening led to an over-detection of breast 
cancer cases by ~30%, and the authors concluded that it is “not clear whether screening 
does more harm than good.”(106)  
 
The issue of over-detection is important, but a review in 2007 of the studies assessing 
over-detection (107) concluded that all the estimates were biased and deemed the 
studies inadequate. They specifically scrutinized the estimates presented by Gotzsche 
(108) (among others) and found that lead-time had not been taken into consideration. 
Lead-time influences the comparison of incidence in screening and control groups since 
it increases the incidence rate of breast cancer in the screening group at both the 
prevalent (the first screen a woman ever does) and subsequent, incident screens. After 
screening stops, the incidence rate drops in the previously screened group. This is due 
to the fact that cancers that would have emerged as symptomatic cancers in this period 
have already been diagnosed at screening. After some years (no exact time point), the 
cumulative incidence will even out between both groups, which is why the comparison 
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of the cumulative incidence should not be made until several years after screening has 
ended. Gotzsche based his comparisons on the cumulative incidence directly at the end 
of screening, and did not statistically adjust for lead-time. This biased all his estimates 
upward, including the estimate of 30% which is referred to in the Cochrane review. 
 
An interesting study from Norway, contributing to the debate about screening, was 
published in 2010 (109). In this study it was shown that there was an effect of 
mammography screening on breast cancer mortality, but that a large part of this 
reduction was attributable to improvements in the healthcare associated with screening, 
e.g. the implementation of interdisciplinary breast cancer teams.  
 
In summary, the studies above all show that mammography screening decreases breast 
cancer mortality. However, more and non-biased studies are needed to evaluate the 
extent of over-detection to be able to adequately assess the pros and cons of screening. 
Furthermore, I personally believe that much would be gained if we could improve 
screening sensitivity for women with highest density, since these are women at high 
risk of breast cancer and where mammography has lowest sensitivity.  
 
 
2.2.6 Breast cancer classification 
Cancers of the breast are almost always adenocarcinomas which originate from the 
epithelial cells. Even so, breast cancer is heterogeneous and can be classified according 
to invasiveness, tumor characteristics, and gene expression patterns. 
 
2.2.6.1 Invasiveness 
Breast cancer is divided into non-invasive and invasive breast cancer. Non-invasive 
cancer is further subdivided into lobular cancer in situ (LCIS) and ductal cancer in situ 
(DCIS). Non-invasive breast cancer has become common since the introduction of 
mammography screening and now accounts for 15-20 % of all breast cancers diagnosed 
in Sweden (7). Throughout the studies of this thesis, the term breast cancer refers to 
invasive breast cancer only. 
 
2.2.6.2 Histopathological classification 
The most common type of invasive cancer histopathologically is ductal cancer, which 
accounts for 40-75% of all invasive breast cancers (7). The second most common type 
of cancer is lobular cancer (5-15%) followed by tubular cancer (2-7%), medullary 
cancer (1-7%), invasive cribriform cancer (0.8-3.5%), mucinous cancer (2%), invasive 
papillary cancer (<1-2%), and invasive micropapillary cancer (<2%) (7). There are 
other types as well but these are even less common.  
 
2.2.6.3 Stage 
Stage is the most important prognosticator to date and is assessed using the TNM-
classification, which incorporates the variables tumor size (T), lymph node involvement 
(N), and presence of distant metastasis (M). Lymph node involvement is the single 
most powerful predictor of prognosis in patients who do not have distant metastasis 
(110), the number of metastatic lymph nodes also strongly, negatively influencing 
survival (111).  
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2.2.6.4 Histologic grade 
Tumor grade was introduced by Greenough in 1925 (112), modified by Bloom and 
Richardson in 1957 (113) and later on in 1991 by Elston and Ellis (114). The latter 
classification is the grading system currently used in Sweden and is commonly referred 
to as the Nottingham histologic grade (NHG), in which a score from 1 to 3 is given 
according to the tubular formation, size and appearance of nuclei (nuclear atypia), and 
number of mitotic cells. The more similar to normal breast tissue the tumor tissue 
appears and the lower the proliferative activity, the lower the grade, and vice versa. 
Grade is a prognostic factor independent of tumor size and lymph node involvement 
but, unlike these factors, is only moderately reproducible (115).  
 
2.2.6.5 Proliferation rate 
Cell division is carefully regulated in normal cells but not in cancer cells where one of 
the most important features is uncontrollable cell growth. All cells go through a cell 
cycle consisting of five phases; G0, G1, S, G2, and M. G0 is a resting phase. During 
G1, cells increase in size. This is also a checkpoint that the cell is ready to enter S-
phase, the synthesis phase, during which DNA replication takes place. During G2 the 
cell continues to grow. This is also a checkpoint to see that the cell is ready to enter M-
phase. If ready, the cell enters M-phase, when mitosis (cell division) takes place, 
producing two identical daughter cells.  
 
During the time period of studies I, III, and IV, proliferation rate was measured using 
flow cytometry as the percentage of cells in S-phase. Nowadays, assessment of Ki67 
and cyclin A, proteins produced during the proliferative part of the cell cycle (i.e. not 
during G0), is carried out instead, using immunohistochemistry. A tumor’s proliferation 
rate influences prognosis, but whether it predicts response to chemotherapy is uncertain 
(116).  
 
2.2.6.6 Hormone receptors 
Breast cancers can be categorized based on estrogen receptor (ER) and progesterone 
receptor (PR) status. This is assessed using immunohistochemistry and predicts 
whether the primary tumor/metastasis will respond to endocrine therapy. A tumor is 
usually considered positive if >10% of the nuclei are stained, but tumors with only 1-
10% stained nuclei may also benefit from endocrine treatment (117). ER-status is the 
most important factor influencing response to endocrine therapy, but PR-status may 
give additional information to ER-positive tumors (118, 119). Apart from predicting 
response to endocrine therapy, hormone-receptor status also influences prognosis; 
hormone receptor-positive cancers conferring a survival advantage compared to 
hormone receptor-negative cancers (120).  
 
2.2.6.7 HER2 (or HER2/neu or ERBB2) 
Human epidermal growth factor receptor 2 (HER2) (also known as HER2-neu and 
ERBB2) is amplified in 10-30% of all breast cancer cases (7). HER2 mediates growth, 
differentiation, and survival of cells. Women whose tumors overexpress HER2 thus 
have a more aggressive disease than women whose tumors do not overexpress HER2, 
both with respect to disease-free and overall survival (121). Assessment of 
amplification of the HER2 gene has come into use in later years and was not carried out 
during the time of the studies included in this thesis. HER2-status is assessed using 
immunohistochemistry followed by in situ hybridization in cases where amplification is 
suspected with immunohistochemistry or where this is inconclusive. Amplification of 
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the HER2 gene allows for treatment with a specific antibody against the HER2-receptor 
(trastuzumab) and was initially introduced in Sweden in 2001 as a treatment of 
metastasized breast cancer but is now also used approved for treatment of non-
metastasized breast cancer. Before the availability of trastuzumab, women with HER2-
positive cancers had a particularly poor prognosis, but now these women, if they are 
treated with trastuzumab, may even have a better prognosis than women with HER2-
negative disease (122). 
 
2.2.6.8 Triple-negative disease 
Tumors that are ER-, PR-, and HER2-negative are referred to as triple-negative tumors 
and account for 15-20% of all newly diagnosed breast cancers (123). Triple-negative 
cancers are associated with younger age, African American ethnicity, and BRCA1-
mutations (124). Since they lack ER- and PR-expression as well as HER-2 
overexpression/gene amplification, there is no targeted therapy for these cancers, but 
they respond to chemotherapy (124). Despite this, triple-negative breast cancers still 
have a higher probability of relapse and poorer overall survival in the first years after 
breast cancer diagnosis compared to other types of breast cancer (123). Most triple-
negative cancers are high-grade tumors and of ductal type. However, both low-grade 
tumors and tumors of other histopathological classification than ductal may be triple-
negative. Most triple-negative breast cancers fall into a specific molecular subgroup of 
breast cancers, the basal group (see below), but the remainder fall into different 
molecular subtypes (see below). In other words, the group of triple-negative tumors is 
diverse (124).  
 
2.2.6.9 Molecular subtypes 
Gene expression profiling has highlighted the concept of breast cancer as a collection 
of different diseases albeit affecting the same organ. Individual subclasses have been 
identified through gene expression profiling, referred to as the Sorlie–Perou subtypes 
(125, 126). The heterogeneity between the subtypes is reflected in differences in 
etiology, clinical presentation, histopathological features, outcomes, and response to 
systemic therapies (127).  
 
The five original subtypes were the luminal A, luminal B, basal-like, ERBB2, and the 
normal breast-like subtypes (125, 126). The claudin-low and molecular apocrine 
subtypes were identified later on (128, 129). Luminal A tumors are mostly ER-positive, 
have a low proliferation rate, and are of low grade. Luminal B tumors are also mostly 
ER-positive but may express low levels of hormone receptors, and are usually of high 
grade and have a higher proliferation rate. The basal-like subtype is often characterized 
by triple-negative tumors (ER-, PR-, and HER2-negative), high levels of expression of 
proliferation-related genes, and expression of genes associated with basal and 
myoepithelial cells. The claudin-low subtype is also often triple-negative. However, the 
claudin-low tumors are characterized by down-regulation of genes involved in cell 
adhesion, are more enriched in epithelial-to-mesenchymal transition features, and 
express stem cell-associated genes (127). The apocrine subtype is usually ER-negative 
but expresses androgen receptors and androgen receptor-associated genes, and has 
histological features suggestive of apocrine differentiation (129, 130). The ERBB2 
subtype shows amplification and high expression of the ERBB2 gene (also known as 
HER2 or HER2-neu). The normal breast-like subtype shows expression of many genes 
expressed by adipose tissue and other non-epithelial cell types, strong expression of 
basal epithelial genes, and low expression of luminal epithelial genes. It is, however, 
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unclear whether the latter subtype is a distinct group or represents poorly sampled 
tissue (131).  
 
The different subtypes can be used as both prognostic and therapeutic predictive 
factors. The luminal A subtype, for example, has a better prognosis than the luminal B 
and basal-like subtypes (127). Further, the basal-like subtype responds well to 
chemotherapy whereas the luminal A subtype does not (127). However, the additive 
prognostic and predictive information offered is limited compared to ER-status, PR-
status, HER2-status, and Ki67 (127). The clear advantage of molecular subtyping lies 
in reproducibility and quantitative assessment (127).  
 
2.2.7 Treatment 
2.2.7.1 Surgery 
Surgery is the primary treatment of breast cancer and many women are cured after 
surgery or after surgery and radiotherapy combined (7). Depending on the size of the 
tumor and its relation to the total breast size, tumor stage, number of tumor foci and 
distance between them, and whether the patient can tolerate radiotherapy or not, either 
partial mastectomy (breast-conserving surgery) or total mastectomy is performed. In 
addition to the surgery of the breast, axillary surgery is also carried out. The primary 
aim of the axillary surgery is to appropriately determine tumor stage in order to plan the 
adjuvant therapy and also assess prognosis. The therapeutic effect of lymph node 
dissection is uncertain; although axillary lymph node dissection protects against 
axillary recurrences, it is unclear whether this effects survival (132-134).  
 
During the time period of the studies within this thesis, i.e. the 1990’s, axillary lymph 
node dissection was the only surgical procedure in routine use. However, axillary 
lymph node dissection is associated with complications such as seroma, infections, and 
lymphedema of the arm. Furthermore, mammography screening caused a shift in the 
stage at which breast cancers were detected, and more and more patients were 
diagnosed without spread to axillary lymph nodes. This made many question the role of 
axillary lymph node dissection and the sentinel node biopsy was therefore developed 
during the end of the 1990’s for staging purposes to reduce morbidity. With this 
method, the first lymph node/s in the axilla draining the breast is/are identified using 
radioactive tracer and blue dye. This/these lymph node/s are then surgically removed 
and analyzed immediately (with the patient still on the operating table). If any spread is 
seen, an axillary lymph node dissection is performed, if not, no further surgery of the 
axilla is carried out. Sentinel node biopsies are currently only performed in women with 
unifocal tumors and where preoperative axillary lymph node status is negative.  
 
2.2.7.2 Radiotherapy 
Postoperative radiotherapy is routinely given to the residual breast tissue of women 
treated with breast-conserving surgery. The purpose of the treatment is to decrease risk 
of local recurrence but postoperative radiotherapy has also been shown to improve 
breast cancer-specific survival (135). However, radiotherapy also increases risk of 
cardiovascular events and decreases overall survival due to this (135). Other less severe 
side-effects include redness of the skin, swelling of the breast, pneumonitis (136), 
lymphedema of the arm (if the axilla is radiated), and possibly also negative effects on 
lung function (7). It is therefore of utter importance to balance risk and benefit. 
International (ASCO and Eusoma) and Swedish guidelines (SweBCG) thus recommend 
that women at high risk of locoregional recurrence (where risk of recurrence within 10 
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years is greater than 20%) should receive post-operative locoregional. According to the 
Swedish guidelines this means that women treated with total mastectomy should 
receive radiotherapy towards the thoracic wall if e.g. the tumor is >5 cm, or receive 
radiotherapy towards both the thoracic wall, axilla, and supraclavicular lymph nodes if 
e.g. there are ≥ 4 metastatic lymph nodes (7). Radiotherapy is usually given in fractions 
of 2 Gy every day, 5 days per week until the patient has received a total dose of 50 Gy 
(7).  
 
2.2.7.3 Systemic therapy 
The aim of systemic therapy is to annihilate micrometastatic disease. Factors that 
predict response to systemic therapy are ER-status, PR-status, and HER-2 
amplification. Proliferation rate, assessed as e.g. Ki67 may add information as to who 
will benefit from chemotherapy. Despite these factors, the response to therapy is not 
certain; individuals will both be under- and over-treated.  
 
2.2.7.3.1 Endocrine therapy 
ER-status and PR-status are predictive of a tumor’s response to endocrine therapy. A 
woman with ER-negative cancer does not benefit from endocrine therapy (7). The 
oldest type of endocrine therapy is the selective estrogen receptor modulator (SERM), 
tamoxifen. It has been in use since the 1970’s and is still an important part of the 
arsenal of endocrine treatment. Tamoxifen reduces risk of recurrence, contralateral 
breast cancer, and breast cancer mortality (137). It is prescribed as a pill to be taken 
daily for usually 5 years. 
 
During the time at which the study subjects within this thesis were treated, tamoxifen 
was the most commonly prescribed type of endocrine therapy. Other forms of 
endocrine therapy were megestron (Megace®), a substance similar to progesterone, and 
goserelin (Zoladex®), an analogue to GnRH which results in medical castration. 
During the 1990’s, aromatase-inhibitors were introduced as an alternative treatment of 
hormone-positive postmenopausal breast cancer, but it was not until the late 1990’s that 
randomized controlled trials were conducted to compare the effect of aromatase 
inhibitors to tamoxifen. A meta-analyses has shown that the former decreases risk of 
recurrence compared to latter (138). However, no statistically significant improvement 
in survival has been shown (137). 
 
2.2.7.3.2 Chemotherapy 
There is no specific predictive factor of response to chemotherapy but according to the 
St Gallen treatment recommendations (117) low expression of the estrogen receptor, 
HER2 amplification, and increased proliferation rates predict response to chemotherapy 
in general. All trials that have evaluated treatment with trastuzumab have also given 
HER2-positive patients chemotherapy, why there is no support of the use of 
trastuzumab without chemotherapy (117). Furthermore, triple-negative patients should 
(almost always) receive chemotherapy. Whether to give chemotherapy to women with 
ER-positive, HER2-negative disease is more problematic; for these patients relative 
indications for chemotherapy include grade 3 tumors, high proliferation rate, ≥4 
positive lymph nodes, tumor size of >5 cm, extensive peritumoral vascular invasion, 
and patient preference (117). 
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Chemotherapy is usually given after surgery, but women with locally 
advanced/primarily inoperable tumors (T3-T4), fixed axillary metastatic lymph nodes, 
or parasternal or supraclavicular metastasis are recommended preoperative 
chemotherapy (neo-adjuvant treatment) (7). Neoadjuvant chemotherapy has the 
potential to decrease tumor size, increasing the possibility of performing breast-
conserving surgery. Although there is no difference in survival depending on whether 
chemotherapy is given before or after surgery, there is an increased risk of locoregional 
recurrence if given before (139). 
  
During the mid 1990’s (and already in the 1980’s) a combination of cyclophosphamide, 
methotrexate, and fluorouracil (CMF) and/or anthracyclins were standardly given, 
especially to premenopausal women with cancers of more advanced stages. Currently 
in Sweden, the decision to use chemotherapy is based on lymph node status. An 
anthracycline-based combination of drugs or CMF is given to lymph node negative 
patients requiring chemotherapy, and lymph node positive patients are recommended a 
more aggressive treatment with anthracycline and taxane-based polychemotherapy (7).  
 
2.2.7.3.3 Antibodies 
Trastuzumab is a monoclonal antibody that binds to the HER2-receptor and impairs 
HER2 signalling, thereby reducing proliferation. It is given to patients with tumors 
showing amplification of the HER2 gene and was initially introduced in Sweden in 
2001 as a treatment of metastasized breast cancer but is now also approved for 
treatment non-metastasized breast cancer (7). Women with HER2-amplified tumors 
should always initially be treated with chemotherapy followed by trastuzumab (7).  
 
2.2.8 Prognosis 
Breast cancer survival has improved drastically over the years due to many factors such 
as adjuvant therapy, mammography screening, and an improved organization. The 
prognosis is generally good and many women are cured by surgery alone. Yet 
approximately 1500 women in Sweden die from breast cancer every year. Unlike most 
other cancers where the 5-year survival often reflects the cure rate, breast cancer has no 
cure rate since women with breast cancer continue to die many years after diagnosis. 
This is naturally also reflected in the development of recurrence; most recurrences 
occur within five years, but a substantial proportion relapses first after five years and 
many years later (140).  
 
The currently used prognostic factors in Sweden are age, stage (tumor size, lymph node 
involvement and distant metastasis), histologic grade, ER-status, PR-status, HER-2-
status, and Ki67 (7). However, studies have also showed that mode of detection 
influences survival – screening-detected cancers have been found to have a better 
prognosis beyond the impact of stage shift compared to cancers detected otherwise 
(141, 142).  
 
Other patient characteristics than age may also influence breast cancer prognosis. High 
BMI, for example, has been shown to confer a poorer prognosis (143) while physical 
activity after diagnosis seems to improve prognosis (144). Ethnicity also affects breast 
cancer outcome: African American women have a poorer survival than non-African 
American women (145). The former are at higher risk of developing triple-negative 
tumors (146) and thereby have a worse prognosis, but Sparano et al. (145) also found a 
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poorer prognosis for African American women with ER-positive cancers and that this 
was independent of e.g. disparities in healthcare. Lastly, time since childbirth is 
inversely associated with survival (147, 148).  
 
HRT has been shown to influence mortality, however, results are contradictory; the 
Women’s Health Initiative (a randomized controlled trial) showed an increased 
mortality for HRT users, whereas observational studies have shown a decreased 
mortality for HRT users (68, 149). This may be due to the fact that HRT users more 
frequently attend mammography than non-HRT users. This will advance the date of 
diagnosis for HRT users, improving survival in observational studies. In the WHI, 
however, mammography attendance was balanced in the comparison arms and could 
therefore not influence results (149).  
 
2.3 MAMMOGRAPHIC DENSITY 
 
2.3.1 Relationship with breast cancer 
It was John Wolfe who in 1976 initially proposed that the mammographic appearance 
of the breast was related to breast cancer risk (150, 151). He created the following 
categorization according to risk: N1 (predominantly fatty breasts); P1 (ductal 
prominence in <25% of the breast); P2 (ductal prominence in ≥25% of the breast); and 
DY (extensive dysplasia). Wolfe showed that the women categorized as DY had a 37-
fold increased incidence of breast cancer compared to the women in the N1 group. 
There was, however, much critique, since Wolfe had performed a cohort study with a 
relatively short follow-up period. Hence, it was believed that the association was due to 
women with dense breasts having masked tumors at study entrance which were then 
diagnosed during the study period. These objections were adequate, but both cohort 
studies with as much as 10 years of follow-up (in which the effect of masking will 
diminish), and case-control studies (in which breast cancers in dense breasts instead 
will be underdiagnosed due to masking) have consistently showed a strong relationship 
between mammographic density and breast cancer (51), although not as high as 
Wolfe’s original estimates.  
 
To achieve a more objective method of assessing density, a semi-automated software, 
Cumulus (152), was developed, which calculates the total breast area, dense and non-
dense areas in mm
2
,
 
and percentage density (PD) by dividing the dense area with the 
total breast area. PD is the most commonly used measurement of density and a meta-
analyses has shown that women with a PD≥75% have a 5-fold increased risk of breast 
cancer than women with PD<5% (51). This makes it the strongest risk factor for breast 
cancer after gender, age and BRCA mutations. However, there is an important 
distinction between high-penetrance genes and mammographic density, because 
whereas the former are fairly uncommon among women with breast cancer 
(approximately 5% of all cases), mammographic density of >50% may account for 
almost 1/3 of all breast cancer cases (153, 154). 
 
2.3.2 Mammographic density assessment 
Mammographic density (MD) reflects the different tissues of the breast. 
Fibroglandular tissue consists of stromal and epithelial cells and is radiodense, 
appearing white on a mammogram, whereas fatty tissue is radiolucent and appears 
black. 
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There are two different ways of assessing density; either qualitatively or 
quantitatively. Wolfe’s parenchymal patterns (151), described previously, and Tabár 
patterns (155) are examples of qualitative assessment. They take into account certain 
features of the breast on a mammogram, such as the appearance of the ducts and 
texture of the tissue, as well as the quantity of density. The American College of 
Radiology created a qualitative, categorical assessment for clinical purposes, BI-
RADS (Breast Imaging-Reporting and Data System) which has largely replaced both 
the Wolfe and Tabár patterns. BI-RADS is categorized accordingly: (1) almost 
entirely fatty, (2) scattered fibroglandular densities, (3) heterogeneously dense, and 
(4) extremely dense. However reliability between readers is modest (kappa 
statistic=0.56) (156). 
 
The software Cumulus is an example of a computer-assisted technique allowing for a 
continuous, quantitative classification of density. In short, two thresholds are set; one 
threshold demarcates the breast from the background (i.e. pixels with a gray value 
equal to or greater than this threshold comprise the total area of the breast) and the 
other threshold separates non-dense from dense tissue (i.e. pixels with a grey value 
equal to or greater than the selected threshold comprise the dense area of the breast) 
(Figure 7). The total breast area, absolute dense area, absolute non-dense area, and 
percentage density (PD) is then calculated by the software. Since Cumulus is a 
technique used for quantitative measurement, the qualitative aspect is lost. 
Nonetheless, PD is still more strongly associated with breast cancer risk than e.g. 
Wolfe patterns (157).  
 
                                    
 
Figure 7. Assessing mammographic density using Cumulus. The pectoralis muscle 
and thoracic wall is demarcated as is the red background. The dense area of the breast 
is encircled/marked. All other tissue in the breast that is not encircled is considered 
non-dense.  
 
There are important limitations with Cumulus. First, it requires digitized, analogue 
films, and is not yet compatible with digital images. Since many mammography units 
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are converting to digital images, this will become an increasing problem for future 
studies. The digitization of images also adds to the work load associated with density 
measurement, which in itself is a laborious task. Secondly, although subjectivity is 
decreased compared to the qualitative techniques, it is not eliminated. For both these 
reasons, fully automated methods are being developed (158, 159). Lastly, density, 
which in reality is a volume, is assessed from 2D films and is estimated as an area. 
New methods are being developed that measure volumetric density. Surprisingly, 
though, the volumetric methods do not give better risk estimations than the area-
based measures (87).  
 
Our group has developed an automated thresholding method using an established 
Java-based image analyses program, ImageJ, for obtaining quantitative measurements 
of mammographic density. We found that it compares well with Cumulus in 
predicting breast cancer risk(159). We also found evidence that ImageJ captured 
additional features of mammograms which were significant and independent markers 
of breast cancer risk (159). We believe that the latter may be a measurement of tissue 
texture. This study was, however, performed on digitized images and the MLO view, 
and must be validated on digital images as well as other views. 
 
2.3.3 Percent versus absolute density 
Most studies assessing density in quantitative terms use the relative measure of density, 
percentage density (PD). However, this does not convey any information about the 
absolute amounts of dense and non-dense tissues. A woman with x amount of dense 
tissue in a small breast will have a higher PD than a woman with the same amount of 
dense tissue in a larger breast (Figure 8). Moreover, two women with the same PD may 
have large differences in the absolute amounts of each respective tissue (Figure 8). On 
the other hand, PD contains information on the non-dense area which the measure of 
absolute density lacks unless one adjusts for the non-dense area. The non-dense area 
may be important, especially in postmenopausal women, since the fatty tissue is an 
important source of local estrogens (160), which influences the dense tissue. 
Furthermore, PD is more intuitive than absolute density and, used as a categorical 
variable, is fairly simple to apply clinically. 
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Figure 8. Percent and absolute density 
 
 
However, since the amount of dense tissue reflects the amount of target tissue for 
carcinogenesis, it has been proposed that inferences on the etiology of mammographic 
density should be made using the absolute measure of density (161). Conversely, PD is 
satisfactory when studying breast cancer risk since both absolute density and percent 
density have been shown to be equally predictive of breast cancer risk (162, 163). 
There is no consensus on which parameter to use when studying mammographic 
density and breast cancer phenotypes/prognosis. 
 
2.3.4 Histology 
Through histological studies increased MD has been shown to be associated with an 
increased amount of stromal cells (164, 165), an increased amount of collagen (164-
166), stromal fibrosis (166, 167), and an increased number of epithelial cells (164, 165, 
168). Interactions between stroma and epithelium are important both in breast 
organogenesis and carcinogenesis and the stromal matrix effects proliferation, 
differentiation, migration, and apoptosis of epithelial cells (37, 39, 169).  
 
Mammographic density has further been hypothesized to correlate with lobular 
involution. Only one group has investigated this relationship (170, 171). They found 
that there was an inverse correlation between mammographic density (assessed using 
the Wolfe patterns) and lobular involution (170), although breasts showing complete 
involution were identified both in the group with mammographically fatty breasts (N1) 
and in the group with densest breasts (DY). In a related study of the same cohort of 
women, they further showed that mammographic density, assessed using the Wolfe 
patterns, and lobular involution were independent risk factors of breast cancer (171); 
the women with no lobular involution and densest breasts having highest risks.   
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2.3.5 Factors influencing mammographic density 
2.3.5.1 Non-genetic factors 
Mammographic density is a dynamic and hormonally responsive trait. It decreases with 
age and during menopause which has been ascribed the process of involution (see 
above). The few existing longitudinal studies have shown a decrease of PD per year of 
~1% (172, 173) and an especially large decrease is seen during menopause when PD 
may decrease by ~3% (173). Parity and increased number of live births decreases 
density, whereas later age at first birth is associated with higher mammographic density 
(174).  
 
Hormone replacement therapy (HRT), especially combined estrogen-progestin 
treatment, increases MD (175). The increase in MD occurs within the first year of use 
(176) and the effect may disappear within three weeks after cessation (177). Lastly, the 
selective estrogen receptor modulator (SERM), tamoxifen, reduces MD (178). Not only 
has tamoxifen been seen to decrease mammographic density, but women whose density 
decreased also had a reduction in breast cancer risk (178). Whether this is true for other 
SERMs, aromatase inhibitors, and chemotherapy, remains to be confirmed (87). 
Although there are many examples of mammographic density as a hormonally 
responsive trait, most studies of mammographic density and blood hormone levels of 
estrogens, progesterone, SHBG, testosterone, and androstenedione have found no 
associations (179). Furthermore, Tamimi et al. found that mammographic density and 
circulating sex hormones were independent risk factors of breast cancer in 
postmenopausal women (180).  
 
BMI is highly, inversely correlated with PD (181, 182). This is due to BMI being 
positively associated with the area of the non-dense tissue, because of an increased 
amount of fatty tissue in the breast. Postmenopausal women with more non-dense 
tissue will have an increased local production of estrogens compared to women with 
less non-dense tissue, which could influence the dense area. In spite of this, BMI seems 
to be only weakly (183), or possibly not at all associated with the absolute dense area of 
the breast (161).  
 
Thus, most factors that influence mammographic density also influence breast cancer 
risk in the same direction, the two exceptions being age and BMI. Boyd et al. (184) 
related mammographic density to the Pike model (50) to try to explain the 
counterintuitive association between mammographic density and age. Pike et al. 
modelled breast cancer incidence as a function of breast tissue aging instead of 
chronological age (50). They proposed that breast tissue aging starts at menarche at a 
certain constant rate until first full-term pregnancy. It then slows and continues at that 
rate until menopause, when it slows even more, and after which it is constant. Pike et 
al. (50) further showed that it was the cumulative exposure to breast tissue aging that 
described the age-incidence curve for breast cancer. Rosner and Colditz extended the 
Pike model to include more breast cancer risk factors (185-187) and proposed that it 
was not breast tissue aging per se that was the underlying cause of breast cancer 
incidence, rather breast tissue aging was a proxy for cell proliferation and accumulation 
of genetic damage due to cumulative hormonal exposure.  Boyd et al. applied this to 
mammographic density and hypothesized that cumulative exposure to mammographic 
density represents the epithelial and stromal cells’ cumulative exposure to hormonal 
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and growth factor stimuli, and that the cumulative exposure to density increases with 
age (157). 
 
2.3.5.2 Genetic factors 
Mammographic density is highly heritable at a given age (188); lifestyle factors only 
explaining 20-30% of the variation in PD between women (189), and >60% of the 
variation attributable to genetic factors (188). As with other quantitative traits, there is 
evidence that the mode of inheritance is polygenic (190), i.e. that several genes are 
involved in the heritability of the disease.  
 
Since mammographic density has been considered an intermediate in breast cancer 
development (184), investigations of associations between genetic variations and 
mammographic density are important to attempt to shed light on breast cancer biology 
and also to possibly find ways of disease prevention. To date, the following breast 
cancer susceptibility genes, ZNF365 (191), LSP1 (192, 193), RAD51L1 (192), ESR1 
(191), and a locus on the long arm of chromosome 8 (193) have been found to correlate 
with mammographic density.  
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3 AIMS OF THIS THESIS 
The overall aim of this thesis has been to investigate whether mammographic density, 
one of the strongest risk factors of breast cancer, also influences the breast cancer 
phenotype and breast cancer progression. We attempted to answer this question through 
the four studies carried out in this thesis. They had the following individual objectives: 
 
 
Study I: To investigate if mammographic density is associated with breast tumor 
characteristics. 
 
Study II: To investigate if mammographic density is associated with molecular 
subtypes of breast cancer. 
 
Study III: To investigate if mammographic density influences breast cancer recurrence 
and survival. 
 
Study IV: To investigate if mammographic density influences survival in interval 
cancers.  
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4 MATERIALS AND METHODS 
4.1 REGISTRIES 
The personal identity number was introduced in 1947. It is a unique 10-digit identifier 
consisting of six digits denoting the birth date (year, month, and day), two digits 
originally specifying the place of birth, but this has been changed so that these two 
digits no longer have a relation to place of birth, one digit to identify the sex of the 
carrier, and, lastly, a control digit. The control digit is calculated given the first nine 
digits so that the entrance of an incorrect number into e.g. a medical record data base 
will give an error message. The personal identity number is registered in all public 
registers, allowing for easy and unequivocal withdrawal and cross-linkage of 
information.  
 
4.2 THE SWEDISH POPULATION REGISTER 
The Swedish Population Register includes information on population statistics such as 
name, personal identity number, place of birth, civil status, address, and 
immigration/emigration data. Population registration is an old tradition originally 
maintained by the church; the oldest preserved records dating back to the early 17
th
 
century.  
 
4.3 THE SWEDISH CANCER REGISTRY 
The Swedish Cancer Registry was established in 1958 and holds information on all 
primary incident cancers diagnosed in Sweden (49). Reporting is mandatory for 
physicians as for pathologists/cytologists separately, which has led to a double 
notification system, and a high degree of completeness. The system also ensures that 
cancers diagnosed at e.g. autopsy are included and are classified according to the 
International Classification of Disease (ICD). 99% of the registered cancers have been 
morphologically verified, and in women, completeness may be as high as 99% (194). 
 
4.4 STOCKHOLM-GOTLAND BREAST CANCER REGISTRY 
All new primary breast cancers diagnosed in the Stockholm-Gotland health care region 
since 1976 have been reported to the Stockholm-Gotland Breast Cancer registry and it 
has a close to complete coverage. An important role of the registry is to evaluate the 
quality of breast cancer care and ensure that patients receive the same care independent 
of place of diagnosis.  
 
4.5 THE CAUSE OF DEATH REGISTRY 
The cause of death register covers all residents in Sweden. It was computerized in 1952 
and is considered reliable since 1961. The reporting is mandatory and there are 
essentially no missing deaths. It has also been shown to correctly classify 98% of breast 
cancer deaths (195). Information in the register includes date of death, underlying cause 
of death, and up to 10 contributing causes, classified according to ICD.  
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4.6 STUDY POPULATIONS 
4.6.1 Paper I, III, and IV 
This study is an extension of a large case-control study, CAHRES, among all Swedish 
residents born in Sweden and aged 50 to 74 years at the time of enrollment, 1 October, 
1993 - 31 March, 1995. Women with incident primary invasive breast cancer were 
identified via the six Swedish Regional Cancer Registries. The study identified 3,979 
women, of whom 84% (n=3345) participated. However, of the cases included, 19 were 
diagnosed outside of the study period, one case had a diagnosis other than breast 
cancer, and 58 cases had non-invasive breast cancer, rendering them ineligible.  
For the studies within this thesis, the inclusion criteria were further refined to only 
include postmenopausal women who had no prior diagnosis of cancer other than non-
melanoma skin cancer. Menopause was defined as the age at the last menstrual period 
or the age at bilateral oophorectomy if at least one year prior to date of study entrance. 
198 premenopausal women and 202 women with unknown menopausal status who 
were younger than 55 for non-smokers or 54 for smokers (the 90th percentile of age at 
natural menopause of study subjects) were thus excluded from the study as were 147 
women with previous cancer. The study base thus consisted of 2720 breast cancer 
cases.  
We used the national registration number to retrieve the correct patient records, and 
collected, among other things, information on tumor characteristics and reason for 
diagnostic mammography (see 4.7.1.3 Data collection of clinical variables).  
Using the Swedish national registration numbers, we obtained addresses for 
participants from 1975 to 1995 through the civil registry. During 2007 and 2008, we 
visited all mammography screening units and radiology departments conducting 
screening mammography throughout Sweden. A second retrieval attempt was carried 
out in 2010-2011. For the eligible participants in these studies, we managed to collect 
mammograms for 2046 women (75%). For all three studies, we used the mammogram 
closest to diagnosis, excluding post-diagnostic mammograms. 107 women who only 
had post-diagnostic mammograms available were thus excluded. The median difference 
from date of mammography to study entrance was 50 days.  
Since studies have shown that MD may differ histologically in pre- and 
postmenopausal women (164) and also may be affected differentially by hormones 
(196, 197), we excluded women who lacked postmenopausal mammograms (n=79).  
Tumors appear white on a mammogram and can thereby distort density measurements. 
Hence, we used the mammogram of the breast contralateral to the tumor, excluding 
women with missing information on tumor side (n=3) or lacking contralateral 
mammograms (n=62, of which 19 had bilateral breast cancer). Images of poor quality, 
including breasts with silicone implants, were also omitted, excluding 21 women. 1774 
women thus comprised the study population of study III. 
Following a decision of the Ethical Review Board of the University of Lund, written 
informed consent was sought to retrieve information from medical records. For study I, 
24 women were excluded due to lack of written consent and another 3 women were 
excluded due to missing medical records. The final study population for this study thus 
included 1747 women. 
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For the fourth study, only women with screening-detected cancers and interval cancers 
were included. We thus used information collected from 66 of the 68 mammography 
units in Sweden from which we had gathered the following: Date and reason for the 
mammographies (screening or referral and reason for referral,) performed within 5 
years before diagnosis, excluding 3 months just before diagnosis to avoid registering 
diagnostic examinations. We added this to the information on mode of detection 
(collected from the medical journals,) to assess interval cancer status for which the 
following definition was applied: Non-screening detected cancers (i.e. reason for 
diagnostic mammography was not screening), where a previous, negative (either 
negative directly at mammography or at follow-up) screening mammography, had been 
conducted 3-24 months before the diagnostic mammography. 24 months was the 
screening-interval in Sweden during the time period of the study. The three-month cut-
off was used to avoid including mammography screenings with clinical work-up 
periods. Out of the 1774 eligible women, 268 women had non-screening detected 
cancers but either a previous screening mammography more than two years prior to 
diagnosis, or no previous screening mammography at all, and 106 individuals lacked 
information to be able to assess interval cancer status. All of these women were 
therefore excluded. Hence, there were 1115 women with screening-detected cancers 
and 285 women with interval cancers which comprised the study population. 
 
Figure 9 depicts the process of study population selection and figure 10 illustrates the 
process of interval cancer assessment. 
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 3979 women, ages 50-74, were diagnosed with incident 
invasive breast cancer in Sweden, October, 1993 –
March, 1995. 634 women did not participate. 
Original CAHRES 
study cohort 
(cases only) 
Previous invasive cancer, n=147 
Non-invasive breast cancer, n=58 
Other diagnosis than breast cancer, n=1 
Diagnosis before or after study period, n=19 
Pre-menopausal, n=198 
Unknown menopausal status and age<54 (smokers) or <55 (non-
smokers), n=202 
 
 
 
Mammograms not found, n=674 
Only post-diagnostic mammograms available, n=107 
Bilateral breast cancer, n=19 
Lacking information on tumor side, n=3 
Lacking contralateral mammogram to tumor side, n=43 
Lack of postmenopausal mammogram, n=79 
Poor image quality, n=21 
 
n=3345 
n=2720 
Not 
eligible  
 
Eligible study subjects 
n=1774 
Figure 9. Flow chart of study populations  
 
Exclusions  
during 
mammogram 
retrieval and 
density 
assessment 
Eligible women 
with density 
measurements 
n=1747 n=1400 
Study 
population 
for study III 
Study 
population 
for study I 
Study 
population  
for study IV 
Lack of written consent to 
obtain medical records, n=24 
No medical records found, n=3 
Clinical cancers, n=268 
Unknown mode of detection, 
n=106 
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Figure 10. Flow chart of study population for study IV 
  
 
4.6.2 Study II 
Study II is also a case-only study. The source population was all women with breast 
cancer operated at a large university hospital in Stockholm (Karolinska University 
Hospital) between 1 January 1994 and 31 December 1996 (n=524), as previously 
described (198). The women were identified through the population-based 
Stockholm-Gotland Breast Cancer Registry. Exclusion was due to refusal of 
participation (n=6), emigration (n=7), lack of frozen tumor (n=231), insufficient 
amount or quality of RNA (n=89), lack of gene expression profiling on U133 A and 
B chips (n=14), neoadjuvant therapy (n=12), in situ cancer (n=5), or stage IV cancer 
(n=1).  
 
The mammogram closest to diagnosis was retrieved for 141 out of the 159 subjects 
with gene expression profiling information. Women with bilateral breast cancer 
(n=10) and subjects with breast implants (n=3) were excluded. We thus had density 
measurements for 128 women. As in the original publication (198), it was not possible 
to assign a unique subtype for all samples. Consequently, n=18 patients were excluded, 
leaving n=110 patients for the final analysis. 
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4.7 DATA COLLECTION AND CLASSIFICATIONS 
4.7.1 Studies I, III, and IV 
4.7.1.1 Questionnaire data 
Data on sociodemographic, anthropometric, hormonal and lifestyle factors, as well as 
family history of breast and ovarian cancer, previous benign breast disease, and 
previous mammography examinations were collected by means of a postal 
questionnaire. The questionnaire included detailed information on HRT including 
brand, dosage, and dates of first and last use of each treatment episode. Pictures of all 
brands marketed in Sweden 1950-1995 were also included to aid recall. If essential 
information was missing in the questionnaire, then cases (and controls) were 
contacted by telephone to obtain this. Approximately 50% of cases were contacted in 
this way. 
 
Since date of mammography was prior to study entrance, the variables age, menopausal 
status, and HRT use were reassessed according to date of mammography. We were not 
able to do this with BMI as we only had information on BMI at study entrance and one 
year prior to study entrance. However, it has previously been shown that inter-
individual variations in BMI are small (199) and the difference in BMI at study 
entrance and one year prior to this was 0.05 units (SD 1.2) for our study participants. 
 
HRT was classified according to recency (current, former, and never use). Since the 
influence of HRT on MD may diminish within three weeks of cessation (176), former 
users were those who discontinued HRT-use more than one month prior to date of 
mammography. There were no individuals classified as never users who started using 
HRT after date of mammography. All compounds, modes of administration, and 
potencies were included in the HRT variable except for low potency, estrogen-only 
pharmaceuticals, since the latter have not been shown to increase breast cancer risk 
(200). 
 
4.7.1.2 Mammographic density data 
Film mammograms of the MLO view were digitized using an Array 2905HD Laser 
Film Digitizer (Array Corporation, Tokyo, Japan), which covers a range of 0 to 4.7 
optical density. The MLO view was used since this was the routine view used at 
mammography screening in Sweden. The density resolution was set at 12-bit spatial 
resolution. We used Cumulus to assess density (152) of the mammogram contralateral 
to the tumor. For each image, a trained observer (LE) set the appropriate gray-scale 
threshold levels defining the edge of the breast and distinguishing dense from non-
dense tissue. The software calculated the total number of pixels within the entire region 
of interest and within the region identified as dense. The percentage density was then 
calculated from these values (dense area/total breast area). The images were measured 
together with approximately the same amount of images for healthy women, and the 
reader was blinded to case-control status and also, naturally, to all variables associated 
with tumor phenotype/prognosis. A random 10% of the images were included as 
replicates to assess the intra-observer reliability, which was high with an R
2
 of 0.92.  
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4.7.1.2.1 Mammographic density 
In study I, III, and IV, mammographic density was treated as a dichotomized variable 
with the cutoff of 25% for high mammographic density, defining the highest quartile in 
our cohort. (Figure 11 depicts mammograms with different PD values also categorized 
based on the 25% cut-off.) We used a categorical variable since this is more clinically 
relevant than a continuous measure and more easily interpreted. An alternative to our 
categorization would be to use the categories introduced by Boyd et al. (157). However, 
these did not fit our postmenopausal study population whose density is lower and more 
homogeneous than a combined pre- and postmenopausal population. N.B. that all 
analyses in study I and III were also performed using PD as a continuous variable. 
Figure 11. Mammograms depicting breasts with different PD values, also categorized 
according to the 25% cut-off used in studies I, III, and IV. 
 
                
a) PD=0%  b)   PD=10% 
  
 
 
c) PD=25%  d) PD=50% 
 
PD<25% 
PD≥25% 
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4.7.1.3 Data collection of clinical variables 
We used the national registration numbers to retrieve patient records and register 
information. Between 2000 and 2002, we collected information on primary surgery, 
adjuvant treatment (endocrine therapy, chemotherapy, and radiotherapy), tumor 
characteristics, possible recurrence, and reason for diagnostic mammography from 
surgical and oncological patient records throughout Sweden.  
 
Grade was classified according to the Nottingham histologic grade or the Bloom–
Richardson scale into three groups. Tumors were considered ER-positive or 
progesterone receptor (PR)-positive if they contained ≥ 0.05 fmol receptor/μg DNA or 
≥ 10 fmol receptor/mg protein.  
 
Type of surgery was classified as partial or total mastectomy independent of axillary 
surgery since 98% of our study participants had axillary lymph node clearance carried 
out.  
 
Mode of detection was treated as a binary variable – screening- vs. non-screening-
detected cancer in studies I and III. This was due to few observations in the categories 
of asymptomatic women referred for mammographic examination, and they were thus 
combined with the group of women with symptomatic cancers.  
 
For information on recurrence variables, see 4.7.1.5 Data on survival variables. 
 
4.7.1.4 Data on interval cancer status 
We visited 66 of the 68 units performing mammographic examinations in Sweden, and 
collected information on the dates and reasons for the examinations (screening or 
referral and reason for referral) performed within 5 years before diagnosis, excluding 3 
months just before diagnosis to avoid registering diagnostic examinations. To evaluate 
whether lack of information on pre-diagnostic mammographies was due to failure in 
finding the information or a true lack of previous mammographies, we compared the 
information retrieved from mammography units to the questionnaire. In the latter, 
women had stated how many mammographies they had undergone 5 years prior to 
diagnosis and this was thus used as reference. N.B., this was only done to distinguish 
between clinical cancers and cancers where we lacked information to assess interval 
cancer status (see Figure 10), and was carried out as quality control. 
4.7.1.5 Data on survival variables 
We collected information on emigrations from the Swedish National Population 
Register, and the date and cause of death until 31 December 2008 from the Swedish 
Causes of Death Registry.  
 
Local recurrence included recurrence in the residual ipsilateral breast, scar tissue, or 
chest wall. Locoregional recurrence included both local recurrences and recurrences in 
regional lymph nodes. During the collection of follow-up information from clinical 
records, the study subjects’ follow-up period was marked as complete or incomplete 
depending on whether follow-up information was complete or missing until date of 
retrieval. Follow-up time for recurrence variables was thus computed from date of 
diagnosis and, depending on outcome, as follows: If recurrence occurred, time to 
specific recurrence; if the specific recurrence did not occur and follow-up information 
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from medical records was considered complete, time to date of medical record retrieval 
or date of death, whichever came first; or, lastly, if information on follow-up was 
considered incomplete, time to last documented date in the medical record or date of 
death, whichever came first.  
 
4.7.2 Study II 
4.7.2.1 Data on patient and tumor characteristics 
We collected information pertaining to status at diagnosis on age, menopausal status, 
HRT, family history, oral contraceptive use, and tumor characteristics from the 
medical records. Breast cancer heredity is defined as history of breast cancer in a 
first-degree relative. Menopausal status was self-assessed by the patient as either pre- 
or postmenopausal. Two women had unknown menopausal status. Both oral 
contraceptive use and HRT use were assessed according to status at time of referral to 
the Karolinska Hospital (former, current, and nonuse, collapsing former and current 
use into one category because of few observations). Non-users of HRT were 
postmenopausal women actively stating no current or previous use of HRT. Of the 
HRT users, approximately two out of three used a combined estrogen and 
progesterone regimen, and one out of three used estrogen only. Local estrogen 
treatment was not considered as HRT use. Oral contraceptive use included all 
preparations.  
 
4.7.2.2 Gene expression data 
Details on RNA preparation and microarray profiling have previously been described 
elsewhere (198). Briefly, frozen tumor was cut into minute pieces and transferred into 
test tubes with RLT buffer (RNeasy lysis buffer, Qiagen, Hilden, Germany), followed 
by homogenization. Proteinase K was then added. After this step, total RNA was 
isolated using Qiagen’s microspin technology. DNase was added to some samples to 
further increase RNA quality. The quality of RNA was assessed by measuring the 
28S:18S ribosomal RNA ratio. Preparation of in vitro transcription products and 
oligonucleotide array hybridization and scanning were performed according to the 
protocol of Affymetrix (Santa Clara, CA, USA). The molecular subtypes have been 
validated previously on a larger cohort of patients (201).  
 
4.7.2.3 Mammographic density data 
The process of digitization of images was the same as for studies I, III, and IV (see 
above).  
 
Two independent observers (ISS and VM) carried out the density measurements 
blinded to the characteristics of the patients and their tumors. Both observers 
measured all of the images and a random repeat sample of 10% of the images. There 
was good inter- and intra-observer reliability with Pearson’s correlation coefficients 
of 0.82 and 0.93, respectively, for absolute density. For our analysis, the density 
measurements from both observers were averaged to minimize random measurement 
error.  
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4.7.3 Statistical analyses 
4.7.3.1 Brief description of statistical analyses used in this thesis 
4.7.3.1.1 Linear regression  
A linear regression model is used to model the relationship between an outcome that is 
continuous and a linear combination of a set of explanatory/predictive variables. In the 
simplest case of one explanatory variable, the model is based on the following 
equation: yi=a+bxi+εi  , where yi is the outcome, xi is the explanatory variable of the ith 
individual/sampling unit, a is the intercept, and b is the slope of the model. The 
relationship is modeled using an error variable εi .  
 
The model is most commonly based on the normal distribution curve – εi is assumed to 
be normally distributed, hence, the outcome is also assumed to be normally distributed. 
The supposed linear relationship should be tested when fitting the model to the data by 
e.g. plotting a simple scatter plot of the exposure and outcome. Furthermore, the 
variance in errors or the outcome variable should be independent of the values of the 
explanatory variables (homoscedasticity), which can be assessed by plotting the 
residual errors against the predicted values. This linear regression model can be used to 
make inferences about the mean value of y (e.g. BMI) given x.  
 
4.7.3.1.2 Logistic regression 
Logistic regression is used for modeling binary outcomes (0 or 1, where 0 could be the 
state healthy and 1 the state diseased). It can be used to estimate the odds ratio, which 
compares the odds of e.g. developing breast cancer given the exposure compared to the 
odds of developing breast cancer given not having the exposure. It models the natural 
logarithm of the odds, which is continuous, as a function of the linear predictor. Instead 
of the normal distribution, the binomial or Bernouilli distribution underlies this model. 
 
The multinomial logistic regression model is a generalization of the binomial logistic 
regression model, and allows for the use of categorical outcomes, such as molecular 
subtypes. There is no implied order for the different values of the outcome.   
 
4.7.3.1.3 The Cox proportional hazards model 
The Cox proportional hazards model is a model used for survival analyses and is used 
to estimate the effect of an exposure on a time-to-event variable, such as recurrence or 
death. A hazards ratio (HR) is calculated. This is the ratio of the hazard rates (e.g. the 
instantaneous rates of dying/failing) for the exposed and unexposed groups. Basic Cox 
proportional hazards models assume that this ratio does not change over time 
(proportional). However, the model assumes nothing of the underlying baseline hazard 
which may vary with time. 
 
4.7.3.2 Study I 
We performed regression analyses treating tumor characteristics as outcomes and 
density as a covariate; we used linear regression for studying tumor size (tumor size 
was transformed by power of 0.2 to obtain an approximately normal distribution), 
multinomial logistic regression for grade and histological classification, and logistic 
regression for all other outcomes. Tests of heterogeneity in effect sizes across 
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subgroups were carried out for grade and histological classification. We included age 
(continuous), BMI (continuous), HRT-use (categorical), age at menarche 
(continuous), previous oral contraceptive use (binary), parity and age at first birth 
combined into one categorical variable (nulliparous, parity ≤2 and age at first birth 
≤25, parity ≤2 and age at first birth >25, parity >2 and age at first birth ≤25, and 
lastly, parity >2 and age at first birth >25), breast feeding ever (binary), age at 
menopause (continuous), previous benign breast disease (binary), family history of 
breast cancer in a first-degree relative (binary), and mode of detection (to try to 
account for masking) as potential confounders. We did not adjust for tumor size, 
presence of lymph node metastasis, or grade since this would risk depleting a true, 
biological effect of density on tumor characteristics or over-adjustment, since mode 
of detection also is associated with these factors. The decision to use covariates as 
continuous or categorical variables was based on the goodness of fit of the model 
which was ascertained using AIC (202).  
 
4.7.3.3 Study II 
Our main variable of interest pertaining to MD was the AD area (measured in cm2), 
owing to the lack of information on BMI. 
 
We analyzed AD as a continuous variable after transformation to the square-root of 
AD to make the density distribution more symmetric. The transformed density values 
were then standardized by subtracting the mean and dividing by the SD (Z scores), to 
be able to interpret the risk estimates in terms of the inherent variability of the density 
values, see below. The relationship between AD and molecular subtypes was 
modelled via multinomial logistic regression. The multinomial model is an extension 
of the logistic regression model that allows for more than two categories in the 
response variable (i.e., subtype). The luminal A subtype was set as reference category 
and we report risk estimates as relative risk ratios (RRRs) for the standardized, 
square-root-transformed AD values. The RRRs reported in Table 3 (page 44) measure 
the change in odds for a tumor falling into any of the reported categories relative to 
the reference category that is associated with an increase of square-root transformed 
AD by one SD (or somewhat less than 25% of the range of densities). 
 
We fitted both an age-adjusted model as well as a fully adjusted model, which took 
into account known correlates of MD and breast cancer risk (age, menopausal status, 
HRT, family history, and oral contraceptive use) (157, 203) and tumor size. The latter 
adjustment was made to try to account for the masking bias and its possible influence 
on molecular subtypes. We have no prior knowledge of whether the factors adjusted 
for influence molecular subtypes, so we chose a conservative approach. Significance 
testing was conducted via likelihood ratio tests. Confidence intervals and P-values for 
individual parameters are based on Wald statistics. All tests were conducted at a 
nominal significance level of a=0.05. 
 
4.7.3.4 Study III 
Survival analyses were carried out using the Cox proportional hazards model to study 
the association between PD and prognostic variables. We included age (continuous), 
BMI (continuous), and HRT-use (categorical) as potential confounders, based on their 
strong association with MD and breast cancer risk (203) and influences on breast 
cancer survival (143, 149, 204). We viewed this as our “crude model” since we were 
not interested in their effect on tumor characteristics but rather the independent effect of 
PD. In the full model we further adjusted for tumor size (continuous), lymph node 
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metastasis (continuous), estrogen receptor(ER)-status (categorical), progesterone 
receptor(PR)-status (categorical), grade (categorical), and mode of detection (binary; 
screening- vs. non-screening-detected cancer). These factors were adjusted for since 
they all influence prognosis (111, 141). Whereas less than 5% of our study population 
were missing information on mode of detection, tumor size, and presence of lymph 
node metastasis, respectively, approximately 30% were missing information on grade, 
ER-, and PR-status. We thus added a missing category to these variables. 
 
4.7.3.5 Study IV 
We studied the influence of PD on survival in interval cancers versus screening-
detected cancers by first comparing survival in interval cancers compared to screening-
detected cancers independent of density, and then stratifying on density (<25% vs. 
≥25%). The Cox proportional hazards model was used to calculate hazard ratios (HR) 
and their associated 95% confidence intervals (95% CI) for 5-year breast cancer-
specific survival. Age at mammography (continuous), BMI (continuous), and HRT use 
(categorical) were included as possible confounders in the first model, further adjusting 
for tumor size (continuous) to try to account for time to diagnosis, or lead-time, in the 
second model.  
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5 MAIN RESULTS 
5.1 STUDY I 
Table 2 shows the results from the analyses of PD and tumor characteristics. PD was 
positively associated with tumor size (regression coefficient 0.031 for tumor size, 
p = 0.017). When we excluded mode of detection from the model, the regression 
coefficient increased slightly and became highly significant (regression coefficient 
0.043, p = 0.001) (results not shown in Table 1). There was a borderline statistically 
significant association between PD and grade 3 tumors (OR 1.56 for grade 3, p = 
0.069). However, a test of heterogeneity revealed that there was no difference in risk 
associated with PD between different categories of grade (p = 0.192). 
 
Re-analyses using PD as a continuous variable gave similar results as those presented, 
i.e., PD was only associated with tumor size (data not shown). 
 
Table 2: Association between percentage density (PD) (≥25% vs. <25%) and tumor 
characteristics* 
Outcome variable Effect size
a
 95% CI p-value 
 (Linear) regression coefficient   
Tumor size    
mm^0.2 0.031 0.005    0.056 0.017 
 Odds ratio (OR)   
ER-status    
ER-negative 1.00 (Ref.)   
ER-positive 1.07 0.72    1.60 0.725 
PR-status    
PR-negative 1.00 (Ref.)   
PR-positive 1.17 0.83    1.66 0.369 
ERPR-status    
ERPR-negative 1.00 (Ref.)   
ERPR-positive 1.31 0.83    2.06 0.247 
Lymph node 
metastasis 
   
Negative 1.00 (Ref.)   
Positive  0.88 0.65    1.19 0.394 
Grade (WHO)    
1 1.00 (Ref.)   
2 1.36 0.85   2.19 0.205
b
 
3 1.56 0.97   2.52 0.069
b
 
Histology    
Ductal 1.00 (Ref.)   
Lobular 1.22 0.82   1.82 0.335 
Other 1.08 0.74   1.57 0.689 
 
a 
Odds ratios in all cases except for tumor size for which a (linear) regression 
coefficient is presented. PD coded as 0= <25%, 1= ≥25%.  
b 
p=0.192 for heterogeneity across subgroups 
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5.2 STUDY II 
Compared with the luminal A subtype (taken as the reference category), the relative 
risk of the luminal B, ERBB2, and normal breast-like subtypes increased with 
increasing AD both in the age adjusted (RRR 1.19, 95% CI 0.58–2.45; RRR 1.88, 
95% CI 0.79–4.48; and RRR 1.51, 95% CI 0.78–2.92, respectively, for an increase in 
square-root-transformed density by one SD) and in the fully adjusted (RRR 1.22, 
95% CI 0.53–2.83; RRR 1.74, 95% CI 0.62–4.85; and RRR 1.43, 95% CI 0.64–3.17, 
respectively) models (Table 3). The relative risk of the basal subtype was essentially 
the same as that of the luminal A subtype in the age-adjusted model (RRR 0.99, 95% 
CI 0.48–2.06), but decreased with increasing AD in the fully adjusted model (RRR 
0.83, 95% CI 0.33–2.10) (Table 3). None of the individual associations were, 
however, statistically significant, nor was the association between AD and molecular 
subtype as a whole statistically significant (p=0.483 and p=0.651 for the age adjusted 
and fully adjusted models, respectively). 
 
Table 3: Relative risk ratios (RRRs) for specific molecular subtypes of breast cancer 
compared to the luminal A subtype for an increase in square-root transformed AD by 
one standard deviation (SD).  
 Age-adjusted* Fully adjusted** 
 RRR   95% CI p-value RRR 95% CI p-value 
Subtype       
Luminal A 1.00 (Ref.)  1.00 (Ref.)  
Luminal B 1.19 0.58-2.45 0.641 1.22 0.53-2.83 0.644 
Basal-like 0.99 0.48-2.06 0.986 0.83 0.33-2.10 0.690 
ERBB2 1.88 0.79-4.48 0.153 1.74 0.62-4.85 0.291 
Normal 
breast-like 1.51 0.78-2.92 0.222 1.43 0.64-3.17 0.385 
*Adjusted for age; p=0.483 for the association between AD and subtype as a whole 
based on the likelihood ratio test. 
**Adjusted for age, oral contraceptive use, menopausal status, HRT use, family history, 
tumor size; p=0.651 for the association between AD and subtype as a whole based on 
the likelihood ratio test. 
 
 
5.3 STUDY III 
Results from survival analyses are reported in Table 4. PD was associated with local 
and locoregional recurrence both before (HR for local recurrence 1∙99, 95% CI 1∙09-
3∙66; HR for locoregional recurrence 1∙84, 95% CI 1∙16-2∙91) and after adjustment for 
established prognosticators (HR for local recurrence 1∙92, 95% CI 1∙03-3∙57; HR for 
locoregional recurrence 1∙67, 95% CI 1∙04-2∙69). No associations between PD, distant 
metastasis, breast cancer-specific survival, and overall survival were observed. 
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Table 4: Association of percentage density (PD) with breast cancer recurrence and 
survival  
 
Adjusted model 1* Adjusted model 2** 
HR
1 CI (95%) p-value HR1 CI (95%) p-value 
Local recurrence 1.99 1.09-3.66 0.026 1.92 1.03-3.57 0.039 
Locoregional 
recurrence 1.84 1.16-2.91 0.010 1.67 1.04-2.69 0.033 
Distant recurrence 1.28 0.90-1.82 0.170 1.08 0.74-1.56 0.698 
5-year breast cancer-
specific survival 1.25 0.82-1.92 0.299 0.97 0.61-1.54 0.908 
10-year breast cancer-
specific survival 1.34 0.97-1.85 0.080 1.08 0.77-1.53 0.644 
Overall 5-year survival 1.07 0.73-1.55 0.742 0.89 0.60-1.32 0.554 
Overall 10-year survival 1.14 0.87-1.48 0.343 0.99 0.75-1.29 0.921 
*Adjusted for age, BMI, and hormone replacement therapy (HRT) use 
** Adjusted for age, BMI, HRT use, mode of detection, tumor size, lymph node 
metastasis, ER-status, PR-status, and grade 
1
 HR=Hazards ratio comparing PD≥25% to PD<25%  
 
 
The associations described in Table 4 between PD and local and locoregional 
recurrence could be due to density masking residual disease in women who were 
operated with partial mastectomy. We therefore redid the analyses pertaining to PD, 
local, and locoregional recurrence, stratifying on surgical procedure (Table 5). For 
women exposed to total mastectomy, the HRs for local and locoregional recurrence 
were 2∙93 (95% CI 1∙03-8∙39) and 2∙16 (95% CI 1∙02-4∙54), respectively, after full 
adjustment. For partially mastectomized women, the HRs for local recurrence and 
locoregional recurrence were 1∙48 (95% CI 0∙67-3∙25) and 1∙57 (95% CI 0∙83-2∙97), 
respectively, after full adjustment. Although the HRs were highest and only statistically 
significant for the group treated with total mastectomy, there was no statistically 
significant difference in the effect of PD on risk of recurrence based on surgical 
procedure, reflected in the non-significant p-values for interaction.  
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Table 5: Association between percentage density (PD≥25% compared to PD<25%) 
and local recurrence stratified on type of surgery 
 
Partial mastectomy
 
Total mastectomy
 
p-value 
for 
inter-
action
2 
HR
1
 CI p-value HR
1 
CI p-value 
Local 
recurrence       
 
Adjustment 1*  1.53 0.70-3.32 0.286 3.44 1.26-9.38 0.016 0.248 
Adjustment 2** 1.48 0.67-3.25 0.334 2.93 1.03-8.39 0.045 0.314 
Locoregional 
recurrence       
 
Adjustment 1* 1.45 0.78-2.70 0.242 2.69 1.34-5.43 0.006 0.238 
Adjustment 2** 1.57 0.83-2.97 0.166 2.16 1.02-4.54 0.044 0.485 
1
HR=Hazards ratio 
2
p-value for interaction testing a possible difference in effects of PD on local and 
locoregional recurrence depending on type of surgery. 
* Adjusted for age, BMI, and hormone replacement therapy (HRT) 
** Adjusted for age, BMI, HRT, mode of detection, tumor size, lymph node metastasis, 
ER-status, PR-status, and grade 
 
 
 
Although we used PD as a binary variable, we also carried out analyses using PD as a 
continuous measure. This did not change the interpretation of the results (data not 
shown).  
 
 
5.4 STUDY IV 
ICs had a particularly unfavorable phenotype compared to screening-detected cancers; 
they were larger (p<0.001), more often lymph node positive (p<0.001), ER-negative 
(p=0.020), PR-negative (0.008), of higher grade (<0.001), and of higher proliferation 
rate (p<0.001) (see Table 2 in manuscript IV). These results were reflected in the 
comparison of ICs in non-dense breasts with screening-detected cancers in non-dense 
breasts. Conversely, in dense breasts, ICs were similar to screening-detected cancers 
except that they were larger (p<0.001), more often presented with lymph node 
metastasis (p=0.001), and of higher grade (p=0.012). Despite the difference in tumor 
size, there was no statistically significant difference in proliferation rates (p=0.523).  
 
According to the Cox proportional hazards model, ICs had a worse prognosis than 
screening-detected cancers, independent of adjustments (Table 6). Both types of ICs 
were associated with a HR of ~3 before adjustment for tumor size. After adjustment for 
tumor size, ICs in non-dense breasts still had a statistically significantly worse survival 
then screening-detected cancers in non-dense breasts (HR of 2.43, 95% CI 1.44-4.10), 
whereas the point estimate approached unity and was statistically non-significant in 
dense breasts (HR 1.41, 95% CI 0.53-3.74).  
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Table 6: Hazard ratios (HRs) comparing 5-year breast cancer-specific survival in 1) 
interval cancers (ICs) to screening-detected cancers 2) only including non-dense breasts 
3) and only including dense breasts  
 ICs compared to 
screening-detected 
cancers, all 
ICs compared to 
screening-detected 
cancers in non-dense 
breasts 
ICs compared to 
screening-detected 
cancers in dense breasts 
HR CI 
(95%) 
p-
value 
HR CI 
(95%) 
p-
value 
HR CI 
(95%) 
p-
value 
Model
1 
3.50 2.25-
5.44 
<0.001 3.62 2.17-
6.06 
<0.001 3.00 1.26-
7.17 
0.013 
Model
2
 2.17 1.36-
3.47 
0.001 2.43 1.44-
4.10 
0.001 1.41 0.53-
3.74 
0.486 
 
1
Adjusted for age, BMI, and hormone replacement therapy (HRT) use. 
2
Adjusted for age, BMI, HRT use, and tumor size. 
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6 DISCUSSION 
6.1 METHODOLOGICAL CONSIDERATIONS 
6.1.1 Study designs 
6.1.1.1 Observational and experimental studies 
Epidemiologic studies can be either observational or experimental. Observational 
studies can be purely descriptive, investigating e.g. the occurrence of disease in a 
certain population. They can also aspire to investigate causes of disease by studying 
associations which is the aim of this thesis.  
 
In an observational study, the assignment of an individual to an exposure is outside of 
the control of the investigator. This leads to important drawbacks including 
confounding and bias (see below), hampering assumptions on causality. In an 
experimental study, on the other hand, a study subject is randomly allocated to a 
treatment (exposure) or control group by the investigator. If carried out properly, i.e. a 
correct randomization process with no cross-over between treatment arms, complete 
follow-up, and double-blind assessment of outcome, the experimental study is 
supposed to be free from systematic errors. Yet the role of chance can still operate in 
both types of studies. To minimize this risk, the study population has to be large, which 
is not always possible, especially in experimental studies. Probably the most important 
limitation of experimental studies, especially in humans, is that they can be unethical to 
perform; one cannot e.g. expose a group of people to a suspected carcinogen to study 
disease etiology. Moreover, certain exposures, e.g. mammographic density, are not 
possible to assign. In these cases we have to rely on animal models and observational 
studies to inform us of disease etiology but be aware of their limitations.  
 
6.1.1.2 Cohort and case-control studies 
A cohort is a group of individuals that is followed for a period of time. A cohort study 
consists of a group of individuals with a certain exposure and a group of individuals 
without the exposure. These two groups are followed for a certain time period and 
comparisons of different outcomes are then made between the two groups. Cohort 
studies are good when it comes to the study of rare exposures and has the advantage 
that one can study the association between the exposure and several different outcomes. 
Further, temporality is known, i.e. it is known that the exposure came before the 
outcome, and this is fundamental when trying to make inferences on causality.  
 
Although a cohort study can initially be created to assess the impact of one exposure on 
different outcomes, it is not uncommon that information on other exposures is collected 
at the same time (or later on). The same cohort can then be re-classified as either 
exposed or non-exposed depending on the next exposure one would want to study. 
 
When an outcome is rare, e.g. breast cancer compared to a cold, it is much more 
efficient to create a study based on individuals with and without the outcome. This is 
called a case-control study and also gives the possibility of studying many different 
exposures at once. Individuals selected as controls have to be identified from the same 
study base as the cases were identified, i.e. if a control had developed the disease under 
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investigation, he/she would have been included as a case in the study. Sampling 
controls from anything but the study base, e.g. comparing female breast cancer cases to 
healthy males, will give rise to selection bias (see below). Since individuals are 
identified when they have developed the outcome (disease), collection of information 
on possible risk factors has to be done retrospectively, which is a limitation of case-
control studies and may give rise to recall bias. This is a specific bias in case-control 
studies due to the ascertainment of exposure occurring after disease development. The 
result may be differences in the likelihood of cases and controls recalling an exposure. 
 
Although studies I, III, and IV all are based on a case-control study, they could be 
considered cohort studies in the sense that they include a cohort of population-based 
breast cancer cases. In line with the benefits of a cohort study, the issue of control 
selection is also irrelevant for all studies. Both exposure and outcomes have been re-
defined compared to the original study, thus, although information from the 
questionnaire was retrospective, recall bias cannot be present. Studies III and IV could 
also be considered prospective since the exposure and all possible confounders were 
assessed (or in the case of mammographic density, mammograms were taken) prior to 
the outcome (recurrence, distant metastasis, or death), thus, temporality is certain. 
However, retrospective collection of mammograms affected the selection of included 
women which is an important limitation of our studies (please see 6.1.2.2.1 Selection 
bias below).  
 
6.1.2 Factors influencing validity 
6.1.2.1 Confounding 
 
 
 
 
 
 
Confounding occurs when the exposure and outcome have common causes. It affects 
the internal validity of the study. If we were to study coffee drinking and lung cancer 
we would most probably see an association since coffee drinkers tend to be smokers. 
To remove the effect of smoking on the relationship between coffee drinking on lung 
cancer, one could e.g. limit the study to non-smokers, adjust for smoking, or stratify on 
smoking.  However, in reality, all confounders are not always known, and/or cannot 
always be accurately measured, resulting in residual confounding (33). 
 
The probability of residual confounding due to lack of adjustment for possible 
confounders seems low in studies I, III, and IV, since we had detailed information on 
many related factors. However, we cannot completely rule out the possibility of 
residual confounding due to confounders that we do not yet know about or due to 
inaccurate assessment of possible confounders.  
 
For study III, we lacked BMI and thus instead used absolute dense area as a measure of 
mammographic density instead of PD. This should have taken care of (or at least 
minimized) any possible confounding by BMI on the relationship between 
E O 
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mammographic density and molecular subtypes. As for the studies above, there may 
also be residual confounding due to unknown confounding factors or inaccurate 
assessment of confounders. 
 
6.1.2.2 Bias 
6.1.2.2.1 Selection bias 
The most important threat to the internal validity of all the studies within this thesis is 
the possibility of selection bias, since all study participants had to have an available 
mammography. However, since only cases were included in the four studies, and 
mammography is one of the fundaments of detecting breast cancer, all cases would at 
least have a mammogram taken at diagnosis. However, the retrieval rate was affected 
for the following reasons: First, it is not uncommon that “healthy” mammograms older 
than 10 years are disposed. Secondly, we used analogue films so some films may have 
been misplaced. Thirdly, each time a woman has a mammogram carried out, old 
mammograms are studied for comparison, therefore, if a woman has an active disease, 
the likelihood of finding the mammograms in the storage area is lower. However, since 
we searched for mammograms in 2007-2009 i.e. >10 years after diagnosis, and events 
(recurrences and contralateral breast cancer) are most common within the first five 
years, it is unlikely that this will be a frequent problem. Further, a second retrieval 
round was carried out in 2010, minimizing this risk. The last and probably most 
important source of possible selection bias lies in the management of deceased 
women’s’ mammograms. These are often stored separately, and not always in order, 
making them more difficult to find. In some cases they are even discarded. This would 
lead to an exclusion of older cases and cases with a more aggressive disease than those 
included.  
 
We did see a small, yet significant age difference between women with and without 
mammograms (62.9 for included women compared to 63.6 for excluded women, 
p=0.015). Nevertheless, selection bias can be controlled for by adjusting for the factors 
influencing selection (33) which we did with age. We could not adjust for vital status. 
Although selection bias can influence the estimation of the strength of the association it 
does not influence the validity of the hypothesis testing. In study III, the finding of a 
null association between mammographic density and survival is valid. In study IV, the 
p-values are also valid, though there is a risk that the strength of the association 
comparing survival in interval cancers to screening-detected cancers may be slightly 
biased due to a selection of survivors. 
 
In study II we had the opposite problem; here subjects were excluded because of lack 
of frozen tumor. Excluded women therefore had a lower mean tumor diameter and 
less often metastatic lymph nodes. There was thus a selection of higher stage tumors 
than that of the source population. This was inevitable because of the harvest of RNA 
requiring a certain amount of tumor tissue. Hence, the results of the study may not be 
generalizable to women with smallest tumors. However, as pointed out above, the 
testing of the null hypothesis is still valid. We found no evidence of an association 
between mammographic density and molecular subtypes, i.e. could not reject the null 
hypothesis. 
 
6.1.2.2.2 Lead-time and length bias 
Comparisons between screening- and non-screening-detected cancers to evaluate the 
efficiency of mammography screening suffer from several biases e.g. selection bias, 
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lead-time bias, and length bias (see 2.2.5.2.4 Biases in estimating the effect of 
screening on mortality). In study IV, we compare the survival of interval cancer cases 
to screening-detected cases, to see if there are true biological differences between them. 
With this aim, only lead-time bias will be a concern. Selection bias will not be present 
since the interval cancer cases originate from the same population as the screening-
detected cancers. The length bias is a true difference in biology - differences in tumors’ 
proliferation rates - and thereby a difference we did not wish to remove. Screening-
detected cancers and interval cancers will, however, have differences in lead-time, 
resulting in an artificial survival advantage for the former compared to the latter. This is 
because interval cancers will be diagnosed at a symptomatic stage, i.e. later in their 
natural history than screening-detected cancers, which mostly will be pre-symptomatic 
and diagnosed earlier in their natural history. Hence, we had to take lead-time into 
account and tried to do so by adjusting for tumor size, a proxy for time to diagnosis. 
 
6.1.2.2.3 Misclassification/information bias  
 
We used Cumulus, a semi-automated thresholding technique to minimized exposure 
misclassification. Further, the intra- and inter-observer reliability was high in all 
studies. For studies I, III, and IV the R
2 
was 0.92 and the reader (LE) regularly 
calibrated herself against the gold standard of Cumulus measurement, test images 
previously read by Professor Norman Boyd (who was one of the developers of 
Cumulus). For study II the Pearson’s rank correlation coefficients were 0.82 and 0.93 
also high for inter- and intra-observer reliability, respectively. Furthermore, we took the 
mean of the density values to minimize measurement error. Nonetheless, exposure may 
have been misclassified in certain individuals. For this misclassification to be 
differential and have biased results, the misclassification of exposure must be 
associated with the outcome (tumor characteristics, molecular subtypes, and prognostic 
variables, respectively), which there is no reason to believe. Yet we cannot completely 
rule out a non-differential misclassification which is a misclassification of exposure not 
related to outcome. This would attenuate results and would therefore be of importance 
in the studies in which we have null findings (e.g. mammographic density and tumor 
characteristics, molecular subtypes, and survival). However, since inter- and intra-
correlation was high throughout, the influence of misclassification should be low.    
 
6.1.2.3 Chance  
Not only can systematic errors influence the results in epidemiologic studies, but 
chance also plays an important role. Increasing the number of participants in a study is 
the best way to reduce its impact. We can also assess the uncertainty of results by 
calculating p-values and confidence intervals (CI).  
 
6.1.2.3.1 The p-value 
In all studies, we construct a null hypothesis (H0) (e.g. that there is no association 
between exposure E and outcome O), and an alternative hypothesis (HA) (there is an 
association between E and O). A p-value measures the certainty with which we can say 
that an observed association (or a more extreme association than the observed) would 
appear by chance. We often use the cut-off of 0.05 for the p-value to discriminate 
between “true” and chance findings. This means that if the p-value<0.05, then there is a 
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5% chance that the observed association (or a more extreme one) would appear by 
chance. If we are only conducting one test, are not conducting multiple tests of the 
same association, and have a probable à priori hypothesis about the relationship, we 
usually deem this a satisfactory cut-off at which to reject the null hypothesis.  
 
The p-value says nothing of the strength of an association; it can be small in a large 
study although the effect of an exposure is weak, and it can be large in a small study, 
although the effect is strong.  
 
6.1.2.3.2 The confidence interval 
In contrast to the p-value, the confidence interval (CI) incorporates both the 
significance and strength of an association. Throughout this thesis, the 95% CI is used 
which means that one can be 95% confident that the “true” value lies within that range. 
If the CI was set at 99%, the confidence that we have captured the true estimate of the 
association would increase, but the width of the CI would also increase. The width of 
the CI is also affected by the size of the study, so that the width increases with smaller 
study samples and vice versa. 
 
6.1.2.4 Type I and type II errors 
Type I and type II errors refer to the erroneous acceptance or rejection of a given null 
hypothesis. A type I error is the rejection of a null hypothesis that is actually true. In 
study III, for example, we found an association between mammographic density and 
local recurrence. However, if there really is no association, we have falsely rejected the 
null hypothesis and have committed a type I error. A type II error occurs if one instead 
erroneously accepts the null hypothesis when it should be rejected. The probability of 
not making a type II error is called the statistical power and is dependent on study size 
and effect size. Study II is an example where a type II error may have occurred. In 
study II, we did not find any association between mammographic density and 
molecular subtypes which could be a result of the relatively small study population. 
Study III is also an example of a possible type II error; in study III we found an 
association between mammographic density and local and locoregional recurrence but 
no association with breast cancer specific survival. If the effect of mammographic 
density on survival is small, we may not have had a large enough study sample to 
observe the association and may therefore have made a type II error. Indeed, it was not 
until the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) conducted a 
large meta-analysis in 2005 that it became clear that locoregional recurrences influence 
survival (48).  
 
6.2 FINDINGS AND INTERPRETATION 
6.2.1 Study I 
Among the tumor characteristics studied, we only found an association between PD and 
tumor size. Interestingly, neither presence of lymph node metastasis nor hormone 
receptor status was associated with PD.  
 
Although there was a statistically significant, positive association between PD and 
tumor size, the effect size was relatively small. The association became more 
pronounced when mode of detection was excluded from the model, lending support to 
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the hypothesis that it is due to masking. However, dense breasts may also give rise to 
more highly proliferative tumors which may be the reason why there still is an 
association between PD and tumor size even after adjustment for mode of detection. To 
try to disentangle the cause of this relationship in an epidemiological study is difficult, 
but an investigation of the association between PD and proliferation rate could give a 
clue to the etiology. Unfortunately, we were not able to study this due to too many 
missing values for proliferation rate (approximately 70% missing values).   
 
Since MD decreases screening sensitivity (90, 205), our à priori hypothesis was that 
density would be correlated with both tumor size and lymph node metastasis. However, 
we found no evidence of an association between PD and the latter. Previous studies 
have been inconsistent (206-210). The ability for breast tumors to metastasize is not 
only dependent on time but also on the acquired ability to invade vessels, survive 
migration, extravasate, and colonize distant sites (45). In agreement with this, Jatoi et 
al. observed that lymph node metastasis was a marker of both time to diagnosis and 
tumor aggressiveness (211). Hence, although density may cause a delay in diagnosis, it 
does not per se imply a direct association with lymph node metastasis.    
 
Although MD is a hormonally responsive trait (212), we saw no association between 
density and hormone receptor status. This is in line with most previous studies (157, 
213) but  is in contrast with another study of postmenopausal women in which higher 
density was associated with increased risk of ER-negative cancers (210). However, 
mode of detection was not accounted for and the proportions of ever-users of HRT 
(76% of the study population) and women with previous benign breast disease (59% of 
the study population) were very high, both of which contribute to increased PD (203, 
214) and increased risk of interval cancers (215, 216). In our study, 50% of the 
participants were ever-users of HRT (including all compounds and modes of 
administration) and 14% had previous benign breast disease. The proportions were the 
same as for women lacking density measurements as was the proportion of ER-
negative cancers. Thus, we believe that our results are representative.  
 
Heusinger et al. recently published a large study on PD and tumor characteristics, 
including both pre-and postmenopausal women, in which they found that PD was 
associated with lower ER-expression (217). However, although highly statistically 
significant, differences in PD between categories of ER-expression were very small, 
and there was no dose-response relationship.  
 
A limitation of this study is that it was solely composed of postmenopausal women; 
hence, our results may not be applicable to premenopausal populations. MD may differ 
histologically in pre- and postmenopausal women (164), and has been shown to be 
influenced by different hormonal factors depending on menopausal status (196, 197). 
Furthermore, both age and menopausal status influence tumor characteristics (146). 
Thus, well-conducted studies are needed to investigate the relationship between MD 
and tumor characteristics in premenopausal women. 
 
6.2.2 Study II 
We found no associations between AD and Sorlie-Perou subtypes; neither between AD 
and individual subtypes, nor between AD and subtype as a whole. However, our study 
population was relatively small and the null findings could simply be due to low power. 
Hence, larger studies are needed to confirm our results.  
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A couple of studies have previously attempted to investigate the association between 
MD and Sorlie-Perou subtypes using receptor status (ER-, PR-, and HER-2-status) as 
proxies for the different molecular subtypes (213, 218-221). Ma et al. (219)
 
studied the 
association between PD and the luminal A and basal-like subtypes and found no 
relationship in case-only analyses. In case-control analyses they observed positive 
associations between PD and both the luminal A and basal-like subtypes, but as these 
associations were of a similar magnitude got they are likely to simply reflect the 
general increase in breast cancer risk associated with PD. Phipps et al. (213) also 
conducted a case-control study investigating the association between density (assessed 
using a visual categorical classification, BI-RADS), ER+, ER-/PR-/HER2+, and triple-
negative breast cancers. They achieved the same results as Ma et al. (219) i.e. that 
density was similarly, positively associated with all subtypes. They concluded that 
although the different subtypes are distinct biological entities, this is not a result of 
differences in the association with MD. We thus believe that our results are in 
agreement with both studies. Arora et al. (218) studied the association between density 
and the luminal A, luminal B, basal-like, and ERBB-2 subtypes also using BI-RADS to 
assess density. They observed that women with extremely dense breasts had a higher 
frequency of luminal A tumors (p=0.05). However, as only age was adjusted for in this 
analysis the findings might have been affected by confounding.  
 
Our findings are in line with most studies relating to the association between MD and 
other tumor characteristics such as hormone-receptor status (157, 222), HER2-status 
(157, 210, 222, 223), and Ki67 (206, 224). Furthermore, most studies addressing the 
relationship between MD and survival have found no association (207, 225-227). We 
find this to be in indirect support of the null association between MD and Sorlie-Perou 
subtypes shown in this study, since molecular subtypes are associated with both tumor 
characteristics and prognosis (228, 229). 
 
6.2.3 Study III 
We found that mammographic density increases risk of local and locoregional 
recurrence after diagnosis of invasive breast cancer. There was no association between 
density and distant metastasis or between density and survival in our postmenopausal 
study population.  
 
A PD of ≥25% nearly doubled the risk of local recurrence compared to women with 
PD<25% and increased the risk of locoregional recurrence by almost 70%, independent 
of established breast cancer prognosticators. The association between PD and 
locoregional recurrence is in agreement with two of three previously published studies 
investigating this relationship (227, 230), although they were both limited to women 
who had undergone breast-conserving surgery.  
 
The relationship between PD and local recurrence could be caused by PD masking 
residual disease after breast-conserving surgery. This reservation is especially 
important in our study since we lacked information on the status of the surgical margin. 
We thus stratified on type of breast surgery and found that the effect was most 
pronounced in the group of women exposed to total mastectomy, undermining this 
hypothesis.  
 
We did not see an association between density and distant recurrence nor with density 
and survival. Distant metastasis is closely linked with breast cancer mortality whereas 
locoregional recurrence has a moderate impact on survival (48). Since we only had 10-
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year follow-up of survival, we cannot exclude that there may be a relationship between 
PD and long term survival, nor can we exclude that there is a small effect of PD on 
survival requiring even larger studies to identify the association. However, our findings 
of a lack of association between MD, distant metastasis, and survival is in accordance 
with both previous studies pertaining to MD and distant metastasis (227, 230), and two 
of three studies on MD and survival (207, 225, 227). The conflicting study relating to 
density and prognosis (226) showed a lower case fatality for women with high density 
compared to women with low density. However, since only age was adjusted for, this 
relationship is most likely due to confounding. 
 
A limitation of our study was that the study population was solely composed of 
postmenopausal women; hence, our results may not be applicable to pre-menopausal 
populations. We also lacked information on HER2 status and Ki67 since they were not 
clinically in use in Sweden at the time our participants were diagnosed with breast 
cancer. Both HER2-status and Ki67 influence prognosis (121, 231). However, for these 
factors to have influenced our results, they must be associated with MD, which there is 
currently no evidence of (210, 219, 223, 224).  
 
6.2.4 Study IV 
We found that ICs, overall, have a worse prognosis than screening-detected cancers. 
Both interval cancers in non-dense and dense breasts (defined as PD<25% and 
PD≥25%, respectively,) had a poorer survival than corresponding screening-detected 
cancers before adjusting for tumor size, a proxy for time to diagnosis. After adjusting 
for tumor size, ICs in non-dense breasts still had a HR of >2 compared to 
corresponding screening-detected cancers. For women with dense breasts, however, 
there was no longer evidence of a statistically significant difference between ICs and 
screening-detected cancers. We thus conclude that ICs in non-dense breasts seem to be 
truly aggressive tumors, whereas the poorer prognosis of ICs in dense breasts compared 
to corresponding screening-detected cancers seems primarily due to differences in time 
to diagnosis.  
 
In support of the above, ICs in non-dense breasts had particularly unfavorable tumor 
characteristics, correlating well with their poorer prognosis. Tumor characteristics in 
ICs in dense breasts were more similar to their corresponding screening-detected 
cancers. However, ICs in dense breasts were larger, more often positive for lymph node 
metastasis, and of higher grade; the first two differences could be in line with the 
hypothesis that these primarily are masked tumors.       
 
A limitation of our study is that our study population was solely composed of 
postmenopausal women. Our results may not be applicable to premenopausal 
populations; hence, studies are needed to investigate the relationship between 
mammographic density, ICs, and survival in premenopausal women.  
 
In conclusion, women with interval cancers had a worse prognosis than women with 
screening-detected cancers. Women diagnosed with ICs in non-dense breasts seemed to 
have a particularly aggressive phenotype and poor prognosis. In women diagnosed with 
ICs in dense breasts, the poorer prognosis seemed primarily due to differences in time 
to diagnosis rather than differences in tumor aggressiveness. Since this is the first study 
of its kind, it is, however, important to verify our findings. If they hold true, future 
studies should focus on establishing the risk factors associated with the more aggressive 
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entity of interval cancers in non-dense breasts, hopefully, allowing for primary 
preventive measures to be taken in the future. 
 
6.3 OVERALL CONCLUSIONS 
Mammographic density does not affect lymph node metastasis, ER-status, PR-status, 
grade, or histopathological classification, but is positively associated with tumor size.   
 
Mammographic density is not associated with molecular subtypes of breast cancer, but 
larger studies are needed to validate our findings. 
 
Mammographic density is an independent risk factor of local and locoregional 
recurrence. 
 
Although high mammographic density increases risk of local and locoregional 
recurrence, it is not associated with distant metastasis or survival. Nonetheless, larger 
studies are needed to rule out a weak association between density and survival. 
 
Interval cancers diagnosed in non-dense breasts seem to be more aggressive than 
corresponding screening-detected cancers.  
 
In dense breasts, there is no evidence of a statistically significantly worse prognosis for 
interval cancers than screening-detected cancers, after taking time to diagnosis into 
account. 
 
In conclusion, out of all phenotypic variables studied, we only found a relationship 
between mammographic density and tumor size, as well as mammographic density and 
local and locoregional recurrence. The latter associations were independent of type of 
surgery; the relationships were actually more pronounced in totally mastectomized 
patients. This is quite surprising – how does mammographic density at diagnosis, 
which is excised, influence recurrence years later? I have two theories: First, there will 
probably be women for whom some breast tissue is left despite a total mastectomy. If 
this tissue is dense rather than non-dense, it may increase the risk of local recurrence in 
the same way it increased the risk of primary breast cancer. Secondly, and more 
speculatively, maybe mammographic density increases risk of self-seeding, which I 
will describe in detail below. 
 
Tumor dissemination was long viewed as a one-way process. However, in 2009, Kim et 
al. (232) showed that disseminated tumor cells could return to the primary tumor and 
re-infiltrate it, a process they referred to as self-seeding. This capacity of re-infiltrating 
the primary tumor was also seen for cells from metastatic colonies.  
 
The self-seeding hypothesis was originally generated when the same research group 
saw that some tumors grew faster than others, despite that the faster-growing tumors 
had lower proliferation rates. Hence, they hypothesized that disseminated tumor cells 
re-colonized the primary tumor. The self-seeded primary tumor could then grow more 
quickly than other unseeded tumors, despite the slower growth rate. They were also 
able to prove this later on (232). 
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It is known that large quantities of tumor cells leave the primary tumor and enter the 
blood stream and that this may occur at early stages (232). However, only a minority of 
these cells give rise to metastasis due to many obstacles, among other things, 
unfavorable conditions at the new site. Self-seeding, on the other hand, does not require 
all of these capacities, since the circulating tumor cell returns “home”, where vessels 
are leaky (easy to extravasate) and the environment familiar (no/little adaptation is 
required) (233).  
 
The primary tumor can either be self-seeded by circulating tumor cells coming directly 
from the primary tumor or from metastatic sites (232). N.B. metastatic tumor cells may 
reside in a dormant manner in a new organ (233), thus, seeding of the primary site does 
not require manifest metastasis. Kim et al. therefore hypothesized that this could 
explain why local recurrence can follow a complete eradication of the primary tumor 
(232).  
 
Mammographic density has been hypothesized to give rise to more aggressive tumors 
due to the increased stromal composition of the breast and increased deposition of 
collagen. Despite this, we and others (227, 230) were not able to show an association 
between mammographic density and risk of distant metastasis. Perhaps, however, 
density does increase risk of dissemination, but maybe these circulating tumor cells 
prefer to colonize or are only capable of colonizing the primary tumor/breast.  
 
The self-seeding hypothesis could thus explain the observed association between 
mammographic density and tumor size, despite that mammographic density has not yet 
been shown to be associated with increased proliferation rate. It would further explain 
the relationship between mammographic density and local and locoregional recurrence, 
in spite of the lacking relationship with distant metastasis. Finally, the strong 
relationship of mammographic density and recurrence in totally mastectomized patients 
would not be as surprising.  
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7 FUTURE PERSPECTIVE 
 
Imagine the endless depth of information a mammography unit holds – mammograms 
for countless women, spanning several years of their lives. Some of these women will 
develop breast cancer and others will not. Some will be cured the minute they get off 
the surgery table, while others will die in spite of all treatments. Who is who? Neither 
our tools of risk prediction nor our prognostic tools are satisfactory. Yet, for many 
years, we neglected the information available within mammograms and are just now 
realizing their potential.   
 
It is now well-established that high mammographic density increases breast cancer risk. 
However, we still lack knowledge of what mammographic density really is and how it 
relates to breast cancer. Not surprisingly, mammographic density seems to be a 
reflection of the number of epithelial and stromal cells in the breast. Some therefore 
believe that density purely is a reflection of the number of cells at risk, but I do not 
think it is that simple. 
 
As both John Wolfe and Laszlo Tabár noted, mammographic density isn’t just white. It 
appears to have different textures – from a flat, homogeneous mass, to multiple round 
little islands, to a rugged, streaky appearance, and so on. Although we did not find that 
quantitative mammographic density was differentially associated with different tumor 
phenotypes, it seems more plausible that qualitative mammographic density is. This 
would be in agreement with studies showing e.g. that the organization of collagen 
affects the degree of malignancy in breast tumors. However, when investigating this, it 
is important that the qualitative measure of density is assessed objectively in order to 
minimize exposure misclassification. Our research group is currently working on an 
automated density assessment tool which incorporates an objective evaluation of 
texture that was shown to add predictive value to breast cancer risk estimates. 
Hopefully, this will also add valuable information pertaining to prognosis.  
 
In clinical practice, we are using a mammogram as a simple means of answering the 
question whether a woman has cancer or not. I believe that a mammogram holds much 
more information than that. We don’t just get a binary value of a tumor, we see the 
qualitative specifics of the tumor and we also see the tumor environment - an important 
factor of carcinogenesis and tumor progression. Furthermore, we can compare the 
mammogram to previous mammograms and, when appropriate, assess interval cancer 
status, and evaluate possible changes in the structure and amounts of the different 
tissues. I think that these variables contain important prognostic information 
independent of established prognosticators. Furthermore, if we could combine this 
information with e.g. histological, cytological, and genetic examinations, I believe that 
we would come a long way in our understanding of breast cancer biology.  
   
We know so much and so little. It appears that for every new answer we get, only more 
questions arise. The complexity of cancer is intriguing, and, at times, also 
overwhelming. Within each field of cancer research we are digging deeper and deeper, 
but we also have to be able to see the big picture and cross the gaps between the 
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disciplines to create new and greater research. Only then can we understand cancer and 
remove the obstacles impeding us from curing and preventing it.  
 60 
 
8 ACKNOWLEDGEMENTS 
First of all, I would like to thank all the women who contributed to the studies within 
this thesis. With your help, we have added another piece to the puzzle, and for every 
little step we take, we are coming closer to being able to eradicate breast cancer. 
I would also like to thank all the personnel at the mammography units for being so kind 
in lending us their mammograms. Furthermore, I would like to express my gratitude to 
the following individuals who all helped me in different ways during this journey: 
 
Per Hall, my main supervisor –It’s been a privilege to work with such a creative mind. 
The way you pursue and execute your high-flying aims in research is inspiring. Thank 
you for letting me work with you, for all the encouragement, and all the fun times 
throughout these years! 
Kamila Czene, my co-supervisor – For all your support – both when things were up 
and when they were down. Your warmth, frankness, and brilliant intellect make it a 
pleasure to work with you!  
Keith Humphreys, my co-supervisor –For being so patient and for always taking your 
time to sit down and talk all the statistical mumbo jumbo through. I appreciate your 
kind and calm way, and for giving me perspective when everything seemed frantic.  
Lena Rosenberg, my co-supervisor –For all the phone talks and e-mails when you’ve 
helped me with both CAHRES and life at large! I appreciate your studious ways and 
always felt confident when you’d read a manuscript.  
Alex Ploner – For all your help and for taking your time to explain statistical issues in 
a very pedagogical way. 
Isabel dos Santos Silva and Valerie McCormack – For your meticulous work and 
insightful critique! 
Hans-Olov Adami, Nancy Pedersen, and Henrik Grönberg – For creating a 
stimulating research environment that I have had the opportunity to enjoy and grow in. 
Tomas Sonnenfeld, my mentor - For your wholehearted support, for taking time from 
your busy schedule to listen to my ideas and problems, and for all the hysterical lunches 
and coffees we’ve had. I can’t imagine having a better mentor than you. 
Hasse Walum – For all our discussions about both the large and small aspects of life. I 
will miss them and you. 
My roomies, Edoardo Colzani and Thang Trinh– For putting up with me and my 
bad habits (although I probably don’t have many  ), for all the discussions and all the 
nonsense, and for making me smile when I’ve been down. 
Mattias Hammarström – For all the lunches and talks – it’s been a pleasure! 
To the rest of the breast cancer group, Maria Sandberg, Anki Kristensen, Ann-
Sofie Andersson, Milka Krestelica, Agneta Lönn, Gerd Agerberg, Ami Rönnberg, 
Krystyna Håkansson, Hatef Darabi, Jingmei Li, Linda Lindström, Ulf Hannelius, 
Daniel Klevebring, Mikael Karlsson, and the list goes on… - For making my time at 
MEB memorable! And to the data collectors – thank you for your tremendous work! 
The MEB faculty, especially Olof Nyrén, Paul Dickman, and Arvid Sjölander – 
For teaching me many issues in epidemiology and biostatistics, and for making it 
enjoyable.  
 61 
 
IT, especially Gunnar Petersson, Gastón Nuñez, Zack Yusof, and Torbjörn 
Gustafsson – For all your help and for including me in the “IT-corridor-gang” when I 
first came to MEB . 
To the administrative staff, especially Camilla Ahlqvist – For all your help, always 
delivered with a smile. 
To all other colleagues at MEB – For contributing to the friendly and stimulating 
atmosphere. 
Fuat Celebioglu – For believing in me and for showing me what a great surgeon is.  
Jerzy Lewin – If it weren’t for you, I would never have embarked upon this path – 
thank you! 
Mikael Hartman – For bringing me to MEB to meet Pelle.  
All my colleagues at Bröstcentrum, Södersjukhuset – Thank you for making my 
clinical work so enjoyable!  
 
 
To all my friends – For true friendship - thank you. 
Lena, Olav, and all my new siblings – For including me in your family, for always 
making me feel welcome, and for caring.  
Martin and Michael – For humbling me  and for being the best big brothers a little 
sister could have. 
Mamma and pappa – For opening the world to me and showing me all the 
possibilities life has to offer. Thank you also for all your endless love and support. 
Lastly, thank you for all your help with Eyvind; without it, this thesis would never have 
been possible.  
David – You are the love of my life. Thank you for everything. 
Eyvind - Eyvind-peyvind, snuse, buse, and älskling - you are my sunshine. 
 
 
 
 
 
 
 
 62 
 
9 REFERENCES 
 
 
 
 
1. U. S. National Institutes of Health NCI. SEER Training Modules, Breast 
Cancer. http://training.seer.cancer.gov/breast/anatomy; 2012. 
2. Sleeman KE, Kendrick H, Robertson D, Isacke CM, Ashworth A, 
Smalley MJ. Dissociation of estrogen receptor expression and in vivo stem cell activity 
in the mammary gland. The Journal of cell biology. 2007;176(1):19-26. Epub 
2006/12/28. 
3. Booth BW, Smith GH. Estrogen receptor-alpha and progesterone receptor 
are expressed in label-retaining mammary epithelial cells that divide asymmetrically 
and retain their template DNA strands. Breast Cancer Res. 2006;8(4):R49. Epub 
2006/08/03. 
4. Oakes SR, Naylor MJ, Asselin-Labat ML, Blazek KD, Gardiner-Garden 
M, Hilton HN, et al. The Ets transcription factor Elf5 specifies mammary alveolar cell 
fate. Genes & development. 2008;22(5):581-6. Epub 2008/03/05. 
5. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-
Labat ML, et al. Generation of a functional mammary gland from a single stem cell. 
Nature. 2006;439(7072):84-8. Epub 2006/01/07. 
6. Sleeman KE, Kendrick H, Ashworth A, Isacke CM, Smalley MJ. CD24 
staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal 
and non-epithelial cells. Breast Cancer Res. 2006;8(1):R7. Epub 2006/01/19. 
7. Swedish Breast Cancer Group S. National guidelines for treatment of 
breast cancer (Nationella riktlinjer för behandling av bröstcancer). 2012 [updated 2012-
02-112012-08-20]; 3.0:[Available from: 
http://www.swebcg.se/Files/Docs/Nationella_riktlinjer120211.pdf. 
8. Gusterson BA, Stein T. Human breast development. Seminars in cell & 
developmental biology. 2012;23(5):567-73. Epub 2012/03/20. 
9. Russo J, Russo IH. Development of the human breast. Maturitas. 
2004;49(1):2-15. Epub 2004/09/08. 
10. Birkenfeld A, Kase NG. Functional anatomy and physiology of the 
female breast. Obstetrics and gynecology clinics of North America. 1994;21(3):433-44. 
Epub 1994/09/01. 
11. Hassiotou F, Geddes D. Anatomy of the human mammary gland: Current 
status of knowledge. Clinical anatomy. 2012. Epub 2012/09/22. 
12. Milanese TR, Hartmann LC, Sellers TA, Frost MH, Vierkant RA, 
Maloney SD, et al. Age-related lobular involution and risk of breast cancer. J Natl 
Cancer Inst. 2006;98(22):1600-7. Epub 2006/11/16. 
13. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates 
of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 
2010;127(12):2893-917. Epub 2011/02/26. 
14. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 
2001;2(9):533-43. Epub 2002/03/22. 
15. Hoover RN. That recognised risk factors can explain past and present 
international differences in breast cancer incidence: misconceptions 5. Br J Cancer. 
2012;107(3):408-10. Epub 2012/07/26. 
16. Tyczynski J, Tarkowski W, Parkin DM, Zatonski W. Cancer mortality 
among Polish migrants to Australia. Eur J Cancer. 1994;30A(4):478-84. Epub 
1994/01/01. 
17. Ziegler RG, Hoover RN, Pike MC, Hildesheim A, Nomura AM, West 
DW, et al. Migration patterns and breast cancer risk in Asian-American women. J Natl 
Cancer Inst. 1993;85(22):1819-27. Epub 1993/11/17. 
18. Bray F, McCarron P, Parkin DM. The changing global patterns of female 
breast cancer incidence and mortality. Breast Cancer Res. 2004;6(6):229-39. Epub 
2004/11/13. 
 63 
 
19. Cancer Statistics (Cancerstatistik) [database on the Internet]. 2012 [cited 
2012-10-07]. Available from: http://192.137.163.49/sdb/can/val.aspx 
www.socialstyrelsen.se. 
20. Cancer Incidence in Sweden 2010: Socialstyrelsen; 2011 [cited 2012 
2012-06-26]. Available from: http://www.socialstyrelsen.se/publikationer2011/2011-
12-15. 
21. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, 
Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy 
postmenopausal women: principal results From the Women's Health Initiative 
randomized controlled trial. Jama. 2002;288(3):321-33. Epub 2002/07/19. 
22. Lambe M, Wigertz A, Holmqvist M, Adolfsson J, Bardage C, Fornander 
T, et al. Reductions in use of hormone replacement therapy: effects on Swedish breast 
cancer incidence trends only seen after several years. Breast Cancer Res Treat. 
2010;121(3):679-83. Epub 2009/11/07. 
23. Bouchardy C, Usel M, Verkooijen HM, Fioretta G, Benhamou S, 
Neyroud-Caspar I, et al. Changing pattern of age-specific breast cancer incidence in the 
Swiss canton of Geneva. Breast Cancer Res Treat. 2010;120(2):519-23. Epub 
2009/07/28. 
24. Canfell K, Banks E, Moa AM, Beral V. Decrease in breast cancer 
incidence following a rapid fall in use of hormone replacement therapy in Australia. 
The Medical journal of Australia. 2008;188(11):641-4. Epub 2008/06/03. 
25. Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ. 
Recent declines in hormone therapy utilization and breast cancer incidence: clinical and 
population-based evidence. J Clin Oncol. 2006;24(33):e49-50. Epub 2006/11/23. 
26. Hemminki E, Kyyronen P, Pukkala E. Postmenopausal hormone drugs 
and breast and colon cancer: Nordic countries 1995-2005. Maturitas. 2008;61(4):299-
304. Epub 2008/11/11. 
27. Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in 
utilisation of hormone replacement therapy. Breast Cancer Res Treat. 2008;107(3):427-
30. Epub 2007/04/25. 
28. Parkin DM. Is the recent fall in incidence of post-menopausal breast 
cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer. 
2009;45(9):1649-53. Epub 2009/02/17. 
29. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer 
EJ, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J 
Med. 2007;356(16):1670-4. Epub 2007/04/20. 
30. Seradour B, Allemand H, Weill A, Ricordeau P. Changes by age in breast 
cancer incidence, mammography screening and hormone therapy use in France from 
2000 to 2006. Bulletin du cancer. 2009;96(4):E1-6. Epub 2009/05/14. 
31. Vankrunkelsven P, Kellen E, Lousbergh D, Cloes E, Op de Beeck L, Faes 
C, et al. Reduction in hormone replacement therapy use and declining breast cancer 
incidence in the Belgian province of Limburg. Breast Cancer Res Treat. 
2009;118(2):425-32. Epub 2009/02/25. 
32. Li CI, Daling JR. Changes in breast cancer incidence rates in the United 
States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol 
Biomarkers Prev. 2007;16(12):2773-80. Epub 2007/12/19. 
33. Adami H-O, Hunter D, Trichopoulos D. Textbook of Cancer 
Epidemiology. Second ed: Oxford University Presss; 2008. 
34. Welfare' SNBoHa. Causes of Death 20102011 2012-09-22. 
35. Dödsorsaksstatistik (Statistics of cause of death) [database on the 
Internet]. 2012. 
36. Cancer Statistics [database on the Internet]. 2011 [cited 120615]. 
Available from: 
www.socialstyrelsen.se/register/halsodataregister/cancerregistret/inenglish. 
37. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 
2000;100(1):57-70. Epub 2000/01/27. 
38. Lazebnik Y. What are the hallmarks of cancer? Nat Rev Cancer. 
2010;10(4):232-3. Epub 2010/04/01. 
39. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. 
Cell. 2011;144(5):646-74. Epub 2011/03/08. 
 64 
 
40. Sonnenschein C, Soto AM. The Society of Cells: Cancer and Control of 
Cell Proliferation. New York, New York: Springer Verlag; 1999. 
41. Weaver VM, Gilbert P. Watch thy neighbor: cancer is a communal affair. 
J Cell Sci. 2004;117(Pt 8):1287-90. Epub 2004/03/17. 
42. Moinfar F, Man YG, Arnould L, Bratthauer GL, Ratschek M, Tavassoli 
FA. Concurrent and independent genetic alterations in the stromal and epithelial cells 
of mammary carcinoma: implications for tumorigenesis. Cancer Res. 2000;60(9):2562-
6. Epub 2000/05/16. 
43. Paszek MJ, Weaver VM. The tension mounts: mechanics meets 
morphogenesis and malignancy. Journal of mammary gland biology and neoplasia. 
2004;9(4):325-42. Epub 2005/04/20. 
44. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. 
Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 
2009;139(5):891-906. Epub 2009/11/26. 
45. Weinberg R. The Biology of Cancer. 1st edn. ed: Garland Science; 2006. 
46. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and 
evolving paradigms. Cell. 2011;147(2):275-92. Epub 2011/10/18. 
47. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. 
Science. 2011;331(6024):1559-64. Epub 2011/03/26. 
48. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. 
Effects of radiotherapy and of differences in the extent of surgery for early breast 
cancer on local recurrence and 15-year survival: an overview of the randomised trials. 
Lancet. 2005;366(9503):2087-106. Epub 2005/12/20. 
49. Welfare SNBoHa. Cancer incidence in Sweden 20102011 2012-06-21. 
50. Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG. 
'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. 
Nature. 1983;303(5920):767-70. Epub 1983/06/30. 
51. McCormack VA, dos Santos Silva I. Breast density and parenchymal 
patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol 
Biomarkers Prev. 2006;15(6):1159-69. Epub 2006/06/16. 
52. Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history 
and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer. 
1997;71(5):800-9. Epub 1997/05/29. 
53. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a 
population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br 
J Cancer. 2000;83(10):1301-8. Epub 2000/10/25. 
54. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et 
al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 
mutations detected in case Series unselected for family history: a combined analysis of 
22 studies. Am J Hum Genet. 2003;72(5):1117-30. Epub 2003/04/05. 
55. Stratton MR, Rahman N. The emerging landscape of breast cancer 
susceptibility. Nature genetics. 2008;40(1):17-22. Epub 2007/12/29. 
56. Fanale D, Amodeo V, Corsini LR, Rizzo S, Bazan V, Russo A. Breast 
cancer genome-wide association studies: there is strength in numbers. Oncogene. 
2012;31(17):2121-8. Epub 2011/10/15. 
57. Key T, Appleby P, Barnes I, Reeves G, Endogenous H, Breast Cancer 
Collaborative G. Endogenous sex hormones and breast cancer in postmenopausal 
women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94(8):606-16. 
Epub 2002/04/18. 
58. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, 
Dowsett M, et al. Endogenous steroid hormone concentrations and risk of breast cancer 
among premenopausal women. J Natl Cancer Inst. 2006;98(19):1406-15. Epub 
2006/10/05. 
59. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous 
estrogen, androgen, and progesterone concentrations and breast cancer risk among 
postmenopausal women. J Natl Cancer Inst. 2004;96(24):1856-65. Epub 2004/12/17. 
60. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast 
cancer. Epidemiologic reviews. 1993;15(1):36-47. Epub 1993/01/01. 
61. Breast cancer and hormone replacement therapy: collaborative reanalysis 
of data from 51 epidemiological studies of 52,705 women with breast cancer and 
 65 
 
108,411 women without breast cancer. Collaborative Group on Hormonal Factors in 
Breast Cancer. Lancet. 1997;350(9084):1047-59. Epub 1999/04/23. 
62. Ewertz M, Duffy SW, Adami HO, Kvale G, Lund E, Meirik O, et al. Age 
at first birth, parity and risk of breast cancer: a meta-analysis of 8 studies from the 
Nordic countries. Int J Cancer. 1990;46(4):597-603. Epub 1990/10/15. 
63. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet 
Oncol. 2001;2(3):133-40. Epub 2002/03/21. 
64. Collaborative Group on Hormonal Factors in Breast C. Breast cancer and 
breastfeeding: collaborative reanalysis of individual data from 47 epidemiological 
studies in 30 countries, including 50302 women with breast cancer and 96973 women 
without the disease. Lancet. 2002;360(9328):187-95. Epub 2002/07/23. 
65. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, 
et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal 
women. J Natl Cancer Inst. 2003;95(16):1218-26. Epub 2003/08/21. 
66. Judd HL, Shamonki IM, Frumar AM, Lagasse LD. Origin of serum 
estradiol in postmenopausal women. Obstet Gynecol. 1982;59(6):680-6. Epub 
1982/06/01. 
67. Green J, Cairns BJ, Casabonne D, Wright FL, Reeves G, Beral V, et al. 
Height and cancer incidence in the Million Women Study: prospective cohort, and 
meta-analysis of prospective studies of height and total cancer risk. Lancet Oncol. 
2011;12(8):785-94. Epub 2011/07/26. 
68. Narod SA. Hormone replacement therapy and the risk of breast cancer. 
Nature reviews Clinical oncology. 2011;8(11):669-76. Epub 2011/08/03. 
69. Lee SA, Ross RK, Pike MC. An overview of menopausal oestrogen-
progestin hormone therapy and breast cancer risk. Br J Cancer. 2005;92(11):2049-58. 
Epub 2005/05/19. 
70. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, 
Gass M, et al. Breast cancer after use of estrogen plus progestin in postmenopausal 
women. N Engl J Med. 2009;360(6):573-87. Epub 2009/02/07. 
71. Kerlikowske K, Cook AJ, Buist DS, Cummings SR, Vachon C, Vacek P, 
et al. Breast cancer risk by breast density, menopause, and postmenopausal hormone 
therapy use. J Clin Oncol. 2010;28(24):3830-7. Epub 2010/07/21. 
72. Trichopoulos D. Hypothesis: does breast cancer originate in utero? 
Lancet. 1990;335(8695):939-40. Epub 1990/04/21. 
73. Michels KB, Xue F. Role of birthweight in the etiology of breast cancer. 
Int J Cancer. 2006;119(9):2007-25. Epub 2006/07/11. 
74. Park SK, Kang D, McGlynn KA, Garcia-Closas M, Kim Y, Yoo KY, et 
al. Intrauterine environments and breast cancer risk: meta-analysis and systematic 
review. Breast Cancer Res. 2008;10(1):R8. Epub 2008/01/22. 
75. Silva Idos S, De Stavola B, McCormack V, Collaborative Group on Pre-
Natal Risk F, Subsequent Risk of Breast C. Birth size and breast cancer risk: re-analysis 
of individual participant data from 32 studies. PLoS Med. 2008;5(9):e193. Epub 
2008/10/03. 
76. Bodian CA. Benign breast diseases, carcinoma in situ, and breast cancer 
risk. Epidemiologic reviews. 1993;15(1):177-87. Epub 1993/01/01. 
77. Longnecker MP. Alcoholic beverage consumption in relation to risk of 
breast cancer: meta-analysis and review. Cancer Causes Control. 1994;5(1):73-82. 
Epub 1994/01/01. 
78. Palmer JR, Rosenberg L. Cigarette smoking and the risk of breast cancer. 
Epidemiologic reviews. 1993;15(1):145-56. Epub 1993/01/01. 
79. Ronckers CM, Erdmann CA, Land CE. Radiation and breast cancer: a 
review of current evidence. Breast Cancer Res. 2005;7(1):21-32. Epub 2005/01/12. 
80. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. 
Projecting individualized probabilities of developing breast cancer for white females 
who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-86. Epub 
1989/12/20. 
81. Gail MH, Costantino JP. Validating and improving models for projecting 
the absolute risk of breast cancer. J Natl Cancer Inst. 2001;93(5):334-5. Epub 
2001/03/10. 
 66 
 
82. Schonfeld SJ, Pee D, Greenlee RT, Hartge P, Lacey JV, Jr., Park Y, et al. 
Effect of changing breast cancer incidence rates on the calibration of the Gail model. J 
Clin Oncol. 2010;28(14):2411-7. Epub 2010/04/07. 
83. Claus EB, Risch N, Thompson WD. The calculation of breast cancer risk 
for women with a first degree family history of ovarian cancer. Breast Cancer Res 
Treat. 1993;28(2):115-20. Epub 1993/11/01. 
84. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer 
in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 
1994;343(8899):692-5. Epub 1994/03/19. 
85. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model 
incorporating familial and personal risk factors. Statistics in medicine. 
2004;23(7):1111-30. Epub 2004/04/02. 
86. Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, et al. 
Evaluation of breast cancer risk assessment packages in the family history evaluation 
and screening programme. Journal of medical genetics. 2003;40(11):807-14. Epub 
2003/11/25. 
87. Assi V, Warwick J, Cuzick J, Duffy SW. Clinical and epidemiological 
issues in mammographic density. Nature reviews Clinical oncology. 2012;9(1):33-40. 
Epub 2011/12/07. 
88. Tice JA, Cummings SR, Ziv E, Kerlikowske K. Mammographic breast 
density and the Gail model for breast cancer risk prediction in a screening population. 
Breast Cancer Res Treat. 2005;94(2):115-22. Epub 2005/11/02. 
89. Barlow WE, White E, Ballard-Barbash R, Vacek PM, Titus-Ernstoff L, 
Carney PA, et al. Prospective breast cancer risk prediction model for women 
undergoing screening mammography. J Natl Cancer Inst. 2006;98(17):1204-14. Epub 
2006/09/07. 
90. Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V. Effect of age, 
breast density, and family history on the sensitivity of first screening mammography. 
Jama. 1996;276(1):33-8. Epub 1996/07/03. 
91. Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, et al. 
Recommendations for follow-up care of individuals with an inherited predisposition to 
cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. Jama. 
1997;277(12):997-1003. Epub 1997/03/26. 
92. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. 
American Cancer Society guidelines for breast screening with MRI as an adjunct to 
mammography. CA: a cancer journal for clinicians. 2007;57(2):75-89. Epub 
2007/03/30. 
93. Robson M, Offit K. Clinical practice. Management of an inherited 
predisposition to breast cancer. N Engl J Med. 2007;357(2):154-62. Epub 2007/07/13. 
94. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, 
Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and 
BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of 
BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21(1):134-47. Epub 
2011/12/07. 
95. Yeatman TJ, Cantor AB, Smith TJ, Smith SK, Reintgen DS, Miller MS, 
et al. Tumor biology of infiltrating lobular carcinoma. Implications for management. 
Annals of surgery. 1995;222(4):549-59; discussion 59-61. Epub 1995/10/01. 
96. Hamilton LJ, Evans AJ, Wilson AR, Scott N, Cornford EJ, Pinder SE, et 
al. Breast imaging findings in women with BRCA1- and BRCA2-associated breast 
carcinoma. Clinical radiology. 2004;59(10):895-902. Epub 2004/09/29. 
97. Tilanus-Linthorst M, Verhoog L, Obdeijn IM, Bartels K, Menke-
Pluymers M, Eggermont A, et al. A BRCA1/2 mutation, high breast density and 
prominent pushing margins of a tumor independently contribute to a frequent false-
negative mammography. Int J Cancer. 2002;102(1):91-5. Epub 2002/09/28. 
98. Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast 
cancer. Jama. 2005;293(10):1245-56. Epub 2005/03/10. 
99. Olsson S, Andersson I, Karlberg I, Bjurstam N, Frodis E, Hakansson S. 
Implementation of service screening with mammography in Sweden: from pilot study 
to nationwide programme. J Med Screen. 2000;7(1):14-8. Epub 2000/05/12. 
 67 
 
100. Welfare SNBoHa. Nationella Riktlinjer för bröstcancersjukvård (Swedish 
National Guidelines for Breast Cancer Healthcare)2007 120923. 
101. Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, 
Watney EA, et al. Breast tumor characteristics as predictors of mammographic 
detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst. 
1999;91(23):2020-8. Epub 1999/12/02. 
102. Chu KC, Smart CR, Tarone RE. Analysis of breast cancer mortality and 
stage distribution by age for the Health Insurance Plan clinical trial. J Natl Cancer Inst. 
1988;80(14):1125-32. Epub 1988/09/21. 
103. Duffy SW, Tabar L, Chen HH, Holmqvist M, Yen MF, Abdsalah S, et al. 
The impact of organized mammography service screening on breast carcinoma 
mortality in seven Swedish counties. Cancer. 2002;95(3):458-69. Epub 2002/09/05. 
104. Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist 
LE. Long-term effects of mammography screening: updated overview of the Swedish 
randomised trials. Lancet. 2002;359(9310):909-19. Epub 2002/03/29. 
105. Tabar L, Vitak B, Chen HH, Yen MF, Duffy SW, Smith RA. Beyond 
randomized controlled trials: organized mammographic screening substantially reduces 
breast carcinoma mortality. Cancer. 2001;91(9):1724-31. Epub 2001/05/04. 
106. Gotzsche PC, Nielsen M. Screening for breast cancer with 
mammography. Cochrane database of systematic reviews. 2011(1):CD001877. Epub 
2011/01/21. 
107. Biesheuvel C, Barratt A, Howard K, Houssami N, Irwig L. Effects of 
study methods and biases on estimates of invasive breast cancer overdetection with 
mammography screening: a systematic review. Lancet Oncol. 2007;8(12):1129-38. 
Epub 2007/12/07. 
108. Gotzsche PC. On the benefits and harms of screening for breast cancer. 
International journal of epidemiology. 2004;33(1):56-64; discussion 9-73. Epub 
2004/04/13. 
109. Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening 
mammography on breast-cancer mortality in Norway. N Engl J Med. 
2010;363(13):1203-10. Epub 2010/09/24. 
110. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node 
status, and survival in 24,740 breast cancer cases. Cancer. 1989;63(1):181-7. Epub 
1989/01/01. 
111. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting 
highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. 
Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J 
Clin Oncol. 2001;19(18):3817-27. Epub 2001/09/18. 
112. Greenough RB. Varying degrees of malignancy in cancer of the breast. J 
Cancer Research. 1925(9):453. 
113. Bloom HJ, Richardson WW. Histological grading and prognosis in breast 
cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J 
Cancer. 1957;11(3):359-77. Epub 1957/09/01. 
114. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. 
The value of histological grade in breast cancer: experience from a large study with 
long-term follow-up. Histopathology. 1991;19(5):403-10. Epub 1991/11/01. 
115. Meyer JS, Alvarez C, Milikowski C, Olson N, Russo I, Russo J, et al. 
Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation 
index: reproducibility of grade and advantages of proliferation index. Mod Pathol. 
2005;18(8):1067-78. Epub 2005/05/28. 
116. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in 
breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11(2):174-83. 
Epub 2010/02/16. 
117. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ, 
et al. Thresholds for therapies: highlights of the St Gallen International Expert 
Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 
2009;20(8):1319-29. Epub 2009/06/19. 
118. Ferno M, Stal O, Baldetorp B, Hatschek T, Kallstrom AC, Malmstrom P, 
et al. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor 
 68 
 
and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden 
Breast Cancer Group. Breast Cancer Res Treat. 2000;59(1):69-76. Epub 2000/04/07. 
119. Stendahl M, Ryden L, Nordenskjold B, Jonsson PE, Landberg G, 
Jirstrom K. High progesterone receptor expression correlates to the effect of adjuvant 
tamoxifen in premenopausal breast cancer patients. Clin Cancer Res. 
2006;12(15):4614-8. Epub 2006/08/11. 
120. Mansour EG, Ravdin PM, Dressler L. Prognostic factors in early breast 
carcinoma. Cancer. 1994;74(1 Suppl):381-400. Epub 1994/07/01. 
121. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. 
Human breast cancer: correlation of relapse and survival with amplification of the 
HER-2/neu oncogene. Science. 1987;235(4785):177-82. Epub 1987/01/09. 
122. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. 
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab 
treatment: an institutional-based review. J Clin Oncol. 2010;28(1):92-8. Epub 
2009/11/26. 
123. Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, et al. 
Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol. 
2012;30(15):1879-87. Epub 2012/03/29. 
124. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast 
cancer: disease entity or title of convenience? Nature reviews Clinical oncology. 
2010;7(12):683-92. Epub 2010/09/30. 
125. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et 
al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52. Epub 
2000/08/30. 
126. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. 
Gene expression patterns of breast carcinomas distinguish tumor subclasses with 
clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-74. Epub 
2001/09/13. 
127. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: 
classification, prognostication, and prediction. Lancet. 2011;378(9805):1812-23. Epub 
2011/11/22. 
128. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et 
al. Identification of conserved gene expression features between murine mammary 
carcinoma models and human breast tumors. Genome biology. 2007;8(5):R76. Epub 
2007/05/12. 
129. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, 
Larsimont D, et al. Identification of molecular apocrine breast tumours by microarray 
analysis. Oncogene. 2005;24(29):4660-71. Epub 2005/05/18. 
130. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, et al. An 
estrogen receptor-negative breast cancer subset characterized by a hormonally 
regulated transcriptional program and response to androgen. Oncogene. 
2006;25(28):3994-4008. Epub 2006/02/24. 
131. Sorlie T. Molecular classification of breast tumors: toward improved 
diagnostics and treatments. Methods in molecular biology. 2007;360:91-114. Epub 
2006/12/19. 
132. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. 
Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total 
mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 
2002;347(8):567-75. Epub 2002/08/23. 
133. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, 
Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with 
invasive breast cancer and sentinel node metastasis: a randomized clinical trial. Jama. 
2011;305(6):569-75. Epub 2011/02/10. 
134. Orr RK. The impact of prophylactic axillary node dissection on breast 
cancer survival--a Bayesian meta-analysis. Annals of surgical oncology. 
1999;6(1):109-16. Epub 1999/02/25. 
135. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. 
Effects of radiotherapy and of differences in the extent of surgery for early breast 
cancer on local recurrence and 15-year survival: an overview of the randomised trials. 
Lancet. 2005;366(9503):2087-106. Epub 2005/12/20. 
 69 
 
136. Lind PA, Wennberg B, Gagliardi G, Fornander T. Pulmonary 
complications following different radiotherapy techniques for breast cancer, and the 
association to irradiated lung volume and dose. Breast Cancer Res Treat. 
2001;68(3):199-210. Epub 2001/12/01. 
137. Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy 
and hormonal therapy for early breast cancer on recurrence and 15-year survival: an 
overview of the randomised trials. Lancet. 2005;365(9472):1687-717. Epub 
2005/05/17. 
138. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, et al. Meta-
analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus 
tamoxifen. J Clin Oncol. 2010;28(3):509-18. Epub 2009/12/02. 
139. Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy 
for women with operable breast cancer. Cochrane database of systematic reviews. 
2007(2):CD005002. Epub 2007/04/20. 
140. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et 
al. Twenty-year follow-up of a randomized trial comparing total mastectomy, 
lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast 
cancer. N Engl J Med. 2002;347(16):1233-41. Epub 2002/10/24. 
141. Joensuu H, Lehtimaki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, 
Kataja V, et al. Risk for distant recurrence of breast cancer detected by mammography 
screening or other methods. Jama. 2004;292(9):1064-73. Epub 2004/09/02. 
142. Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Role of 
detection method in predicting breast cancer survival: analysis of randomized screening 
trials. J Natl Cancer Inst. 2005;97(16):1195-203. Epub 2005/08/18. 
143. Ewertz M, Jensen MB, Gunnarsdottir KA, Hojris I, Jakobsen EH, Nielsen 
D, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol. 
2011;29(1):25-31. Epub 2010/12/01. 
144. Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, 
McTiernan A, Alfano CM. Physical activity, biomarkers, and disease outcomes in 
cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104(11):815-40. Epub 
2012/05/10. 
145. Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, et al. 
Race and hormone receptor-positive breast cancer outcomes in a randomized 
chemotherapy trial. J Natl Cancer Inst. 2012;104(5):406-14. Epub 2012/01/18. 
146. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et 
al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. 
Jama. 2006;295(21):2492-502. Epub 2006/06/08. 
147. Rosenberg L, Thalib L, Adami HO, Hall P. Childbirth and breast cancer 
prognosis. Int J Cancer. 2004;111(5):772-6. Epub 2004/07/15. 
148. Daling JR, Malone KE, Doody DR, Anderson BO, Porter PL. The 
relation of reproductive factors to mortality from breast cancer. Cancer Epidemiol 
Biomarkers Prev. 2002;11(3):235-41. Epub 2002/03/16. 
149. Chlebowski RT, Anderson GL. Changing concepts: Menopausal 
hormone therapy and breast cancer. J Natl Cancer Inst. 2012;104(7):517-27. Epub 
2012/03/20. 
150. Wolfe JN. Risk for breast cancer development determined by 
mammographic parenchymal pattern. Cancer. 1976;37(5):2486-92. Epub 1976/05/01. 
151. Wolfe JN. Breast patterns as an index of risk for developing breast 
cancer. AJR Am J Roentgenol. 1976;126(6):1130-7. Epub 1976/06/01. 
152. Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ. The quantitative 
analysis of mammographic densities. Phys Med Biol. 1994;39(10):1629-38. Epub 
1994/10/01. 
153. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. 
Mammographic density and the risk and detection of breast cancer. N Engl J Med. 
2007;356(3):227-36. Epub 2007/01/19. 
154. Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, et al. 
Mammographic features and breast cancer risk: effects with time, age, and menopause 
status. J Natl Cancer Inst. 1995;87(21):1622-9. Epub 1995/11/01. 
 70 
 
155. Gram IT, Funkhouser E, Tabar L. The Tabar classification of 
mammographic parenchymal patterns. European journal of radiology. 1997;24(2):131-
6. Epub 1997/02/01. 
156. Kerlikowske K, Grady D, Barclay J, Frankel SD, Ominsky SH, Sickles 
EA, et al. Variability and accuracy in mammographic interpretation using the American 
College of Radiology Breast Imaging Reporting and Data System. J Natl Cancer Inst. 
1998;90(23):1801-9. Epub 1998/12/05. 
157. Boyd NF, Martin LJ, Yaffe MJ, Minkin S. Mammographic density and 
breast cancer risk: current understanding and future prospects. Breast Cancer Res. 
2011;13(6):223. Epub 2011/11/26. 
158. Heine JJ, Scott CG, Sellers TA, Brandt KR, Serie DJ, Wu FF, et al. A 
novel automated mammographic density measure and breast * cancer risk. J Natl 
Cancer Inst. 2012;104(13):1028-37. Epub 2012/07/05. 
159. Li J, Szekely L, Eriksson L, Heddson B, Sundbom A, Czene K, et al. 
High-throughput mammographic density measurement: a tool for risk prediction of 
breast cancer. Breast Cancer Res. 2012;14(4):R114. Epub 2012/08/01. 
160. Thijssen JH. Local biosynthesis and metabolism of oestrogens in the 
human breast. Maturitas. 2004;49(1):25-33. Epub 2004/09/08. 
161. Haars G, van Noord PA, van Gils CH, Grobbee DE, Peeters PH. 
Measurements of breast density: no ratio for a ratio. Cancer Epidemiol Biomarkers 
Prev. 2005;14(11 Pt 1):2634-40. Epub 2005/11/15. 
162. Stone J, Ding J, Warren RM, Duffy SW, Hopper JL. Using 
mammographic density to predict breast cancer risk: dense area or percentage dense 
area. Breast Cancer Res. 2010;12(6):R97. Epub 2010/11/23. 
163. Stone J, Warren RM, Pinney E, Warwick J, Cuzick J. Determinants of 
percentage and area measures of mammographic density. Am J Epidemiol. 
2009;170(12):1571-8. Epub 2009/11/17. 
164. Guo YP, Martin LJ, Hanna W, Banerjee D, Miller N, Fishell E, et al. 
Growth factors and stromal matrix proteins associated with mammographic densities. 
Cancer Epidemiol Biomarkers Prev. 2001;10(3):243-8. Epub 2001/04/17. 
165. Li T, Sun L, Miller N, Nicklee T, Woo J, Hulse-Smith L, et al. The 
association of measured breast tissue characteristics with mammographic density and 
other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev. 
2005;14(2):343-9. Epub 2005/03/01. 
166. Alowami S, Troup S, Al-Haddad S, Kirkpatrick I, Watson PH. 
Mammographic density is related to stroma and stromal proteoglycan expression. 
Breast Cancer Res. 2003;5(5):R129-35. Epub 2003/08/21. 
167. Fisher ER, Palekar A, Kim WS, Redmond C. The histopathology of 
mammographic patterns. Am J Clin Pathol. 1978;69(4):421-6. Epub 1978/04/01. 
168. Ghosh K, Brandt KR, Reynolds C, Scott CG, Pankratz VS, Riehle DL, et 
al. Tissue composition of mammographically dense and non-dense breast tissue. Breast 
Cancer Res Treat. 2012;131(1):267-75. Epub 2011/08/31. 
169. Wiseman BS, Werb Z. Stromal effects on mammary gland development 
and breast cancer. Science. 2002;296(5570):1046-9. Epub 2002/05/11. 
170. Ghosh K, Hartmann LC, Reynolds C, Visscher DW, Brandt KR, Vierkant 
RA, et al. Association between mammographic density and age-related lobular 
involution of the breast. J Clin Oncol. 2010;28(13):2207-12. Epub 2010/03/31. 
171. Ghosh K, Vachon CM, Pankratz VS, Vierkant RA, Anderson SS, Brandt 
KR, et al. Independent association of lobular involution and mammographic breast 
density with breast cancer risk. J Natl Cancer Inst. 2010;102(22):1716-23. Epub 
2010/11/03. 
172. Maskarinec G, Pagano I, Lurie G, Kolonel LN. A longitudinal 
investigation of mammographic density: the multiethnic cohort. Cancer Epidemiol 
Biomarkers Prev. 2006;15(4):732-9. Epub 2006/04/15. 
173. Boyd N, Martin L, Stone J, Little L, Minkin S, Yaffe M. A longitudinal 
study of the effects of menopause on mammographic features. Cancer Epidemiol 
Biomarkers Prev. 2002;11(10 Pt 1):1048-53. Epub 2002/10/12. 
174. Boyd NF, Lockwood GA, Martin LJ, Knight JA, Byng JW, Yaffe MJ, et 
al. Mammographic densities and breast cancer risk. Breast disease. 1998;10(3-4):113-
26. Epub 2005/02/03. 
 71 
 
175. Warren R. Hormones and mammographic breast density. Maturitas. 
2004;49(1):67-78. Epub 2004/09/08. 
176. Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S. Changes in 
breast density associated with initiation, discontinuation, and continuing use of 
hormone replacement therapy. Jama. 2001;285(2):171-6. Epub 2001/02/15. 
177. Colacurci N, Fornaro F, De Franciscis P, Mele D, Palermo M, del 
Vecchio W. Effects of a short-term suspension of hormone replacement therapy on 
mammographic density. Fertility and sterility. 2001;76(3):451-5. Epub 2001/09/05. 
178. Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, et al. 
Tamoxifen-induced reduction in mammographic density and breast cancer risk 
reduction: a nested case-control study. J Natl Cancer Inst. 2011;103(9):744-52. Epub 
2011/04/13. 
179. Martin LJ, Boyd NF. Mammographic density. Potential mechanisms of 
breast cancer risk associated with mammographic density: hypotheses based on 
epidemiological evidence. Breast Cancer Res. 2008;10(1):201. Epub 2008/01/30. 
180. Tamimi RM, Byrne C, Colditz GA, Hankinson SE. Endogenous hormone 
levels, mammographic density, and subsequent risk of breast cancer in postmenopausal 
women. J Natl Cancer Inst. 2007;99(15):1178-87. Epub 2007/07/27. 
181. Boyd NF, Martin LJ, Sun L, Guo H, Chiarelli A, Hislop G, et al. Body 
size, mammographic density, and breast cancer risk. Cancer Epidemiol Biomarkers 
Prev. 2006;15(11):2086-92. Epub 2006/11/23. 
182. Brisson J, Morrison AS, Kopans DB, Sadowsky NL, Kalisher L, Twaddle 
JA, et al. Height and weight, mammographic features of breast tissue, and breast cancer 
risk. Am J Epidemiol. 1984;119(3):371-81. Epub 1984/03/01. 
183. Boyd NF, Lockwood GA, Byng JW, Little LE, Yaffe MJ, Tritchler DL. 
The relationship of anthropometric measures to radiological features of the breast in 
premenopausal women. Br J Cancer. 1998;78(9):1233-8. Epub 1998/11/20. 
184. Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, Yaffe MJ, et al. 
Mammographic breast density as an intermediate phenotype for breast cancer. Lancet 
Oncol. 2005;6(10):798-808. Epub 2005/10/04. 
185. Rosner B, Colditz GA, Willett WC. Reproductive risk factors in a 
prospective study of breast cancer: the Nurses' Health Study. Am J Epidemiol. 
1994;139(8):819-35. Epub 1994/04/15. 
186. Rosner B, Colditz GA. Nurses' health study: log-incidence mathematical 
model of breast cancer incidence. J Natl Cancer Inst. 1996;88(6):359-64. Epub 
1996/03/20. 
187. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years 
according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol. 
2000;152(10):950-64. Epub 2000/11/25. 
188. Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MR, 
et al. Heritability of mammographic density, a risk factor for breast cancer. N Engl J 
Med. 2002;347(12):886-94. Epub 2002/09/20. 
189. Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA. 
Association of mammographically defined percent breast density with epidemiologic 
risk factors for breast cancer (United States). Cancer Causes Control. 2000;11(7):653-
62. Epub 2000/09/08. 
190. Varghese JS, Thompson DJ, Michailidou K, Lindstrom S, Turnbull C, 
Brown J, et al. Mammographic breast density and breast cancer: evidence of a shared 
genetic basis. Cancer Res. 2012;72(6):1478-84. Epub 2012/01/24. 
191. Lindstrom S, Vachon CM, Li J, Varghese J, Thompson D, Warren R, et 
al. Common variants in ZNF365 are associated with both mammographic density and 
breast cancer risk. Nature genetics. 2011;43(3):185-7. Epub 2011/02/01. 
192. Vachon CM, Scott CG, Fasching PA, Hall P, Tamimi RM, Li J, et al. 
Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated 
with mammographic density measures that predict breast cancer risk. Cancer Epidemiol 
Biomarkers Prev. 2012;21(7):1156-66. Epub 2012/03/29. 
193. Odefrey F, Stone J, Gurrin LC, Byrnes GB, Apicella C, Dite GS, et al. 
Common genetic variants associated with breast cancer and mammographic density 
measures that predict disease. Cancer Res. 2010;70(4):1449-58. Epub 2010/02/11. 
 72 
 
194. Helgesson O, Bengtsson C, Lapidus L, Merck C, Sparen P. Malignant 
disease observed in a cohort of women. A validation of Swedish Cancer Registry data. 
Scandinavian journal of social medicine. 1994;22(1):46-9. Epub 1994/03/01. 
195. Nystrom L, Larsson LG, Rutqvist LE, Lindgren A, Lindqvist M, Ryden 
S, et al. Determination of cause of death among breast cancer cases in the Swedish 
randomized mammography screening trials. A comparison between official statistics 
and validation by an endpoint committee. Acta Oncol. 1995;34(2):145-52. Epub 
1995/01/01. 
196. Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE. 
Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic 
density. Cancer Res. 2000;60(14):3744-8. Epub 2000/08/05. 
197. Tamimi RM, Hankinson SE, Colditz GA, Byrne C. Endogenous sex 
hormone levels and mammographic density among postmenopausal women. Cancer 
Epidemiol Biomarkers Prev. 2005;14(11 Pt 1):2641-7. Epub 2005/11/15. 
198. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, et al. Gene 
expression profiling spares early breast cancer patients from adjuvant therapy: derived 
and validated in two population-based cohorts. Breast Cancer Res. 2005;7(6):R953-64. 
Epub 2005/11/11. 
199. Livshits G, Malkin I, Williams FM, Hart DJ, Hakim A, Spector TD. 
Longitudinal study of variation in body mass index in middle-aged UK females. Age 
(Dordr). 2011. Epub 2011/08/20. 
200. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. 
Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement 
therapy. Int J Cancer. 1999;81(3):339-44. Epub 1999/04/21. 
201. Calza S, Hall P, Auer G, Bjohle J, Klaar S, Kronenwett U, et al. Intrinsic 
molecular signature of breast cancer in a population-based cohort of 412 patients. 
Breast Cancer Res. 2006;8(4):R34. Epub 2006/07/19. 
202. Akaike H. A new look at the statistical model identification. IEEE 
Transactions on Automatic Control. 1974;19:716-23. 
203. Vachon CM, van Gils CH, Sellers TA, Ghosh K, Pruthi S, Brandt KR, et 
al. Mammographic density, breast cancer risk and risk prediction. Breast Cancer Res. 
2007;9(6):217. Epub 2008/01/15. 
204. Narod SA. Breast cancer in young women. Nature reviews Clinical 
oncology. 2012;9(8):460-70. Epub 2012/06/27. 
205. Mandelson MT, Oestreicher N, Porter PL, White D, Finder CA, Taplin 
SH, et al. Breast density as a predictor of mammographic detection: comparison of 
interval- and screen-detected cancers. J Natl Cancer Inst. 2000;92(13):1081-7. Epub 
2000/07/06. 
206. Aiello EJ, Buist DS, White E, Porter PL. Association between 
mammographic breast density and breast cancer tumor characteristics. Cancer 
Epidemiol Biomarkers Prev. 2005;14(3):662-8. Epub 2005/03/16. 
207. Chiu SY, Duffy S, Yen AM, Tabar L, Smith RA, Chen HH. Effect of 
baseline breast density on breast cancer incidence, stage, mortality, and screening 
parameters: 25-year follow-up of a Swedish mammographic screening. Cancer 
Epidemiol Biomarkers Prev. 2010;19(5):1219-28. Epub 2010/04/22. 
208. Roubidoux MA, Bailey JE, Wray LA, Helvie MA. Invasive cancers 
detected after breast cancer screening yielded a negative result: relationship of 
mammographic density to tumor prognostic factors. Radiology. 2004;230(1):42-8. 
Epub 2003/12/26. 
209. Sala E, Solomon L, Warren R, McCann J, Duffy S, Luben R, et al. Size, 
node status and grade of breast tumours: association with mammographic parenchymal 
patterns. Eur Radiol. 2000;10(1):157-61. Epub 2000/02/09. 
210. Yaghjyan L, Colditz GA, Collins LC, Schnitt SJ, Rosner B, Vachon C, et 
al. Mammographic breast density and subsequent risk of breast cancer in 
postmenopausal women according to tumor characteristics. J Natl Cancer Inst. 
2011;103(15):1179-89. Epub 2011/07/29. 
211. Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK. Significance of axillary 
lymph node metastasis in primary breast cancer. J Clin Oncol. 1999;17(8):2334-40. 
Epub 1999/11/24. 
 73 
 
212. Boyd NF, Martin LJ, Yaffe MJ, Minkin S. Mammographic density: a 
hormonally responsive risk factor for breast cancer. J Br Menopause Soc. 
2006;12(4):186-93. Epub 2006/12/21. 
213. Phipps AI, Buist DS, Malone KE, Barlow WE, Porter PL, Kerlikowske 
K, et al. Breast Density, Body Mass Index, and Risk of Tumor Marker-Defined 
Subtypes of Breast Cancer. Ann Epidemiol. 2012. Epub 2012/03/01. 
214. Byrne C, Schairer C, Brinton LA, Wolfe J, Parekh N, Salane M, et al. 
Effects of mammographic density and benign breast disease on breast cancer risk 
(United States). Cancer Causes Control. 2001;12(2):103-10. Epub 2001/03/15. 
215. Brekelmans CT, Peeters PH, Faber JA, Deurenberg JJ, Collette HJ. The 
epidemiological profile of women with an interval cancer in the DOM screening 
programme. Breast Cancer Res Treat. 1994;30(3):223-32. Epub 1994/01/01. 
216. Kavanagh AM, Mitchell H, Giles GG. Hormone replacement therapy and 
accuracy of mammographic screening. Lancet. 2000;355(9200):270-4. Epub 
2000/02/16. 
217. Heusinger K, Jud SM, Haberle L, Hack C, Adamietz BR, Meier-
Meitinger M, et al. Association of mammographic density with hormone receptors in 
invasive breast cancers - results from a case-only study. Int J Cancer. 2012. Epub 
2012/03/07. 
218. Arora N, King TA, Jacks LM, Stempel MM, Patil S, Morris E, et al. 
Impact of breast density on the presenting features of malignancy. Ann Surg Oncol. 
2010;17 Suppl 3:211-8. Epub 2010/10/01. 
219. Ma H, Luo J, Press MF, Wang Y, Bernstein L, Ursin G. Is there a 
difference in the association between percent mammographic density and subtypes of 
breast cancer? Luminal A and triple-negative breast cancer. Cancer Epidemiol 
Biomarkers Prev. 2009;18(2):479-85. Epub 2009/02/05. 
220. Arora N, King TA, Jacks LM, Stempel MM, Patil S, Morris E, et al. 
Impact of breast density on the presenting features of malignancy. Annals of surgical 
oncology. 2010;17 Suppl 3:211-8. Epub 2010/10/01. 
221. Phipps AI, Buist DS, Malone KE, Barlow WE, Porter PL, Kerlikowske 
K, et al. Breast density, body mass index, and risk of tumor marker-defined subtypes of 
breast cancer. Ann Epidemiol. 2012;22(5):340-8. Epub 2012/03/01. 
222. Eriksson L, Czene K, Rosenberg L, Humphreys K, Hall P. The influence 
of mammographic density on breast tumor characteristics. Breast Cancer Res Treat. 
2012;134(2):859-66. Epub 2012/06/20. 
223. Heusinger K, Jud SM, Haberle L, Hack CC, Adamietz BR, Meier-
Meitinger M, et al. Association of mammographic density with hormone receptors in 
invasive breast cancers: Results from a case-only study. Int J Cancer. 2012. Epub 
2012/03/07. 
224. Heusinger K, Jud SM, Haberle L, Hack CC, Fasching PA, Meier-
Meitinger M, et al. Association of mammographic density with the proliferation marker 
Ki-67 in a cohort of patients with invasive breast cancer. Breast Cancer Res Treat. 
2012. Epub 2012/09/01. 
225. Gierach GL, Ichikawa L, Kerlikowske K, Brinton LA, Farhat GN, Vacek 
PM, et al. Relationship between mammographic density and breast cancer death in the 
breast cancer surveillance consortium. J Natl Cancer Inst. 2012;104(16):1218-27. Epub 
2012/08/23. 
226. Olsen AH, Bihrmann K, Jensen MB, Vejborg I, Lynge E. Breast density 
and outcome of mammography screening: a cohort study. Br J Cancer. 
2009;100(7):1205-8. Epub 2009/03/19. 
227. Cil T, Fishell E, Hanna W, Sun P, Rawlinson E, Narod SA, et al. 
Mammographic density and the risk of breast cancer recurrence after breast-conserving 
surgery. Cancer. 2009;115(24):5780-7. Epub 2009/11/11. 
228. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. 
Gene expression patterns of breast carcinomas distinguish tumor subclasses with 
clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-74. Epub 
2001/09/13. 
229. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. 
Breast cancer classification and prognosis based on gene expression profiles from a 
 74 
 
population-based study. Proc Natl Acad Sci U S A. 2003;100(18):10393-8. Epub 
2003/08/15. 
230. Park CC, Rembert J, Chew K, Moore D, Kerlikowske K. High 
mammographic breast density is independent predictor of local but not distant 
recurrence after lumpectomy and radiotherapy for invasive breast cancer. Int J Radiat 
Oncol Biol Phys. 2009;73(1):75-9. Epub 2008/08/12. 
231. de Azambuja E, Cardoso F, de Castro G, Jr., Colozza M, Mano MS, 
Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of 
published studies involving 12,155 patients. Br J Cancer. 2007;96(10):1504-13. Epub 
2007/04/25. 
232. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, 
et al. Tumor self-seeding by circulating cancer cells. Cell. 2009;139(7):1315-26. Epub 
2010/01/13. 
233. Comen E, Norton L, Massague J. Clinical implications of cancer self-
seeding. Nature reviews Clinical oncology. 2011;8(6):369-77. Epub 2011/04/28. 
 
 
